[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stomach-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stomach-neoplasms":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,33,0,25,[9,41,74,104,136,170,199,226,253,276,323,351,378,407,435,460,491,525,551,572,596,621,647,668,701],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100564511","phase-2-perioperative-therapies-in-locally-advanced-unresectable-gastric-cancer-100564511",false,"NCT06630130","Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer","A Phase II Platform Trial of Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer (Neo-VIKTORY)","Inclusion Criteria:\n\n1. Provision of fully informed consent prior to any study specific procedures.\n2. Patients must be ≥ 19 years of age\n3. Have a life expectancy of at least 12 weeks\n4. Body weight \\> 30kg( \\> 35kg for Rilvegostomig)\n5. Has a Pathologically documented adenocarcinoma of gastric or gastroesophageal junction with HER2 IHC results.\n6. In Cohort A＆B, HER2 positive (HER2 IHC 3+ or HER2 IHC 2+\u002FISH positive) In Cohort C＆D, CLDN18.2 positive\n7. Locally advanced unresectable disease by physician's discretion (ex. cT4 or bulky Nx node or localized peritoneal seeding) No evident distant organ metastasis.\n8. ECOG performance status PS 0-1 with no deterioration between screening and the first dose of study treatment.\n9. Has LVEF ≥ 50% by either echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before treatment\n10. Has measurable target disease assessed by the Investigator based on RECIST version 1.1 before surgery.\n11. Has adequate organ and bone marrow, liver and renal function within 14 days before treatment Note: Transfusion (red blood cell or platelet) or G-CSF administration is not allowed within 14 days prior to the day on which bone marrow function is assessed, or at any time after this day and prior to C1D1.\n\n -Hemoglobin ≥ 9.0 g\u002FdL\n\n -Platelet count ≥100 x 109\u002FL\n\n -Absolute neutrophil count (ANC) ≥ 1.5 x 109\u002FL\n\n -Total bilirubin ≤ 1.5 ULN if no liver metastases \\\u003C 3×ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) at baseline\n * AST (SGOT)\u002FALT (SGPT) ≤ 3.0 x ULN\n * Serum albumin (≥ 3.0g \u002FdL\n * CrCL(Ccr) ≥30mL\u002Fmin (\\> 45ml\u002Fmin in Rilvegostomig or Sone-Ve and ≥50ml\u002Fmin in combine with capecitabine) as determined by Cockcroft Gault (using actual body weight)\n * International normalised ratio or Prothrombin time and either partial thromboplastin or activated partial thromboplastin time ≤ 1.5 × ULN\n12. Female patients must be using a highly effective method of contraception (refer to the restrictions on P45) during the clinical trial and for 7 months after permanent discontinuation of the study drug. There must be evidence that patients are not breastfeeding, have a negative pregnancy test, or not of childbearing potential by meeting one of the following criteria at screening:\n\n 1. Post-menopausal women defined as aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatment.\n 2. Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, but not tubal ligation.\n 3. Amenorrhoeic for 12 months and serum follicle-stimulating hormone (FSH), lutenizing hormone (LH) and plasma oestradiol levels in the postmenopausal range for the institution More detailed information is provided in Appendix G (Definition and accepted contraception for women of childbearing age).\n\nAlso female participants must not breastfeed and must not donate\u002Fretrieve ova from screening to 60 days post last dose in Rilvegostomig, or 7months after last Sone-Ve dose.\n\n13\\. Non-sterilized male patients who are sexually active with a female partner of childbearing potential must use a condom with spermicide from screening to 4 months after the final dose of IMP in Rilvegostomig, or 7months after last Sone-Ve or durvalumab dose. Complete heterosexual abstinence for the duration of the study and drug washout period is an acceptable contraceptive method if it is in line with the patient's usual lifestyle (consideration must be made to the duration of the clinical trial); however, periodic or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable. It is strongly recommended for the female partners of a male patient to also use at least one highly effective method of contraception throughout this period. In addition, male patients should refrain from fathering a child, or freezing or donating sperm from the time of randomisation\u002Fenrolment, throughout the study and for 4 months after the last dose of IMP in Rilvegostomig, or 7months after last Sone-Ve dose or durvalumab dose. Preservation of sperm should be considered prior to enrollment in this study.\n\nExclusion Criteria:\n\n* 1\\. Patients with evident peritoneal metastasis (including tumor cells in peritoneal fluid) or distant metastasis 2. Known dihydropyrimidine dehydrogenase (DPD) enzyme deficiency based on either local or central laboratory testing. Central laboratory testing will be available for patients where testing is SOC and with unknown DPD status.\n\n 3\\. CNS metastases or CNS pathology including epilepsy, seizures, aphasia, or stroke within 3 months prior to consent, severe brain injury, dementia, Parkinson's disease, neurodegenerative diseases, cerebellar disease, severe uncontrolled mental illness, psychosis, and CNS involvement of autoimmune diseases.\n\n 4\\. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, uncontrolled hypertension, serious chronic gastrointestinal conditions associated with nausea, vomiting, diarrhea unstable or active peptic ulcer disease or digestive tract bleeding, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirement, substantially increase risk of incurring AEs, or compromise the ability of the participant to give written informed consent.\n\n 5\\. Unresolved toxicities of including but not limited to peripheral neuropathy, sensory or motor ≥ Grade 2 (Common Terminology Criteria for Adverse Events \\[CTCAE\\] v5.0) from prior therapy (excluding vitiligo, alopecia, endocrine disorders that are controlled with replacement hormone therapy, asymptomatic laboratory abnormalities).\n\n 6\\. History of organ transplant. 7. Active primary immunodeficiency(or history of active primary immunodeficiency)\u002Factive infectious diseases. Active or prior documented autoimmune or inflammatory disorders (including IBD \\[e.g. Crohn's disease, ulcerative colitis or diverticulitis\\], SLE, sarcoidosis syndrome, tuberculosis, Wegener syndrome, myasthenia gravis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, at screening, , that requires use of immunosuppressives, glomerulonephritis, nephritic syndrome, Fanconi Syndrome or renal tubular acidosis within the past 2 years prior to the start of treatment. The following are exceptions to this criterion:\n* Subjects with vitiligo or alopecia, hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement or psoriasis not requiring systemic treatment; patients with coeliac disease controlled by diet alone and patients without active disease in the last 5 years may be included after consultation with Chief Investigator.\n\n 8\\. History of drug induced (non-infectious) ILD\u002Fpneumonitis requiring oral or intravenous steroids, current ILD\u002Fpneumonitis, or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening.\n\n 9\\. Active hepatitis B (HBV surface antigen \\[HBsAg\\] positive) or active hepatitis C. Virus testing is not essential for clinical trial feasiblity assessment. Patients who have had or have resolved HBV infection or HCV infection in the past may participate in clinical trials. Note: For HBsAg-, patient needs to be \\>6 months off antiviral treatment 10. Participants with past or resolved HBV infection are eligible only if they meet all of the following criteria\\*:\n\n • Anti-HBc (+) (IgG or total Ig),\n\n • HBV DNA undetectable,\n\n • Absence of cirrhosis or fibrosis on prior imaging or biopsy,\n * Absence of HCV co-infection or history of HCV co-infection.\n * Access to a local Hepatitis B expert during and after the study. Such participants should be closely monitored for HBV reactivation. . Consideration should be given to exclusion of all participants with HBV infection if comparator or combination study treatments are associated with a high risk of HBV infection reactivation are incompatible with anti-viral medications.\n\n 11\\. Known to have tested positive for human immunodeficiency virus (HIV) (positive HIV 1\u002F2 antibodies) or active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice). Active or prior documented history of primary immunodeficiency at screening. And HIV infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: A. undetectable viral RNA for 6 months, B. CD4+ count \\>350 cells\u002FμL, C. no history of AIDS-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks in Rilvegostomig, or 6 months in Sone-Ve on the same anti-HIV medications (meaning there are no expected further changes in that time to the number or type of antiretroviral drugs in the regimen).\n\nIf an HIV infection meets the above criteria, monitoring of viral RNA load and CD4+ count is recommended. Participants must be tested for HIV if acceptable by local regulations or an institutional IRB\u002FIEC.\n\n12\\. Patient with any of the following cardiac criteria:\n\n* Mean QT interval corrected for heart rate (QTc) ≥ 470 ms calculated from electrogram (ECG) using Friderecia's correction\n* Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block, second degree heart block, PR Interval \\>250 msec.\n* Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, uncorrectable chronic hypokalaemia, congenital long QT syndrome, family history (first-degree relatives) of long QT syndrome or unexplained sudden death under 40 years of age or concomitant medication known to prolong the QT interval\n* Uncontrolled hypotension: systolic BP \\\u003C 90 mmHg and\u002For diastolic BP 60 mmHg or clinically relevant orthostatic hypotension, including a fall in blood pressure of \\> 20 mmHg\n* Atrial fibrillation with a ventricular rate \\>100 bpm on ECG at rest\n* Symptomatic congestive heart failure (NYHA grade II-IV)\n* Known reduced LVEF \\\u003C 55%\n* Prior or current cardiomyopathy of any etiology\n* Prior or current acute myocardial infarction within the past 6 months\n* Severe valvular heart disease\n* Uncontrolled angina (Canadian Cardiovascular Society grade II-IV despite medical terapy)\n* Stroke or transient ischaemic attack in prior to screening\n* Acute coronary syndrome within 6 months prior to starting treatment 13. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 7 months after the last dose of Trastuzumab deruxtecan and Capecitabine or Rilvegostomig.\n\n 14\\. Any investigational agents or study interventions from a previous clinical study: 28 days or 5 half-lives (whichever is shorter).\n\n 15\\. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.\n\n 16\\. Current or prior use of immunosuppressive medication within 14 days before the first dose of investigational product is excluded.\n\nThe following are exceptions to this criterion:\n\n1. Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intraarticular injection).\n2. Systemic corticosteroids at physiological doses not to exceed 10 mg\u002Fday of prednisone or equivalent.\n3. Steroids as premedication for hypersensitivity\u002Finfusion reactions And: Receipt of live attenuated vaccine within 30 days prior to the first dose of study intervention.\n\n Note: Participants should not receive live vaccine while receiving study intervention and up to -90 days after the last dose of study intervention.\n\n 17\\. (For Rilvegostomig): Serious chronic gastrointestinal conditions associated with diarrhea (e.g., active inflammatory bowel disease); active non-infectious skin disease (including any grade rash, urticarial, dermatitis, ulceration, or psoriasis) requiring systemic treatment, active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment.\n\n 18\\. (For Sone-Ve): History of thromboembolic events within the past 3 months prior to the scheduled first dose of study intervention. Participants with venous thromboembolism, who either do not require treatment or who have already been stable on treatment with anticoagulants for 3 months or longer prior to start of study intervention may be enrolled and should be closely monitored.\n * Acute coronary syndrome\u002Facute myocardial infarction\u002Funstable angina pectoris +\u002F- coronary intervention with PCI\u002FCABG\n * D-Dimer \\> 2 ULN considering thromboembolic events as potential risks 19. (For Sone-Ve): Uncontrolled hypertension (defined as systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg) Participant has known clinically significant corneal disease (e.g., active keratitis or corneal ulcerations).\n\n 20\\. (For Sone-Ve): Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable.\n\n 21\\. (For Sone -Ve): Uncontrolled diabetes or diabetic neuropathy within 3 months prior to randomization 22. (For Sone-Ve): Peripheral neuropathy, sensory or monitor ≥ CTCAE Grade 2 at screening","ALL","19 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Gastric cancer (GC) is the fifth most commonly diagnosed cancer, with over one million cases diagnosed annually worldwide. Human epidermal growth factor receptor 2 (HER2) overexpression in GC (seen in 4.4% to 53.4% of patients in different reports) is predictive biomarker of response to HER2-targeting therapies.\n\nTrastuzumab in combination with cisplatin or oxaliplatin, and a fluoropyrimidine (capecitabine or 5-fluorouracil \\[5-FU\\]), is approved anti-HER2 therapy for first-line treatment of HER2-positive gastric or gastroesophageal junction (GEJ) cancer.\n\nRilvegostomig 750 mg Q3W was selected as recommended Phase 2 dose based on all available ARTEMIDE-01 clinical safety, efficacy, PK, RO data as well as modeling analysis. The dose of 750 mg Q3W is predicted to achieve intra-tumoral RO of ≥ 90% in the majority of participants across a broad spectrum of conditions.\n\nThis is a phase II study to initially assess the efficacy of perioperative Trastuzumab Deruxtecan (T-DXd) and Capecitabine combination with or without Rilvegostomig in patients with HER2 positive locally advanced unresectable GC and potentially by subsequent protocol amendment in HER2 low locally advanced GC. Other agents may also subsequently be assessed in this protocol, by protocol amendments .\n\n\\---------------------------------------------------------------------------------------------------- Therefore, these studies provide robust evidence that immune checkpoint inhibitors plus chemotherapy, specifically the perioperative durvalumab plus FLOT regimen, can increase pCR rate and significantly improve long-term survival outcomes for patients with resectable gastric, GEJ, or esophageal cancer.",[27],"Stomach Neoplasms","RECRUITING","2026-06-29",{"date":31,"type":32},"2026-07-01","ACTUAL",{"date":34,"type":32},"2025-01-22",{"date":36,"type":21},"2029-06-30",{"name":38,"class":39},"Jeeyun Lee","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":60,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":4,"leadSponsor":71,"locationsCount":40},"100205406","tissue-procurement-and-natural-history-study-of-patients-with-malignant-mesothelioma-100205406","NCT01950572","Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma","Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma and Other Mesothelin Expressing Cancers","* INCLUSION CRITERIA:\n* All participants \\>= 2 years of age with malignant mesothelioma.\n* All participants \\>=18 years of age with thymic carcinoma, pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers or other solid tumor known to express mesothelin.\n* Confirmed pathological diagnosis is required\n* Ability and willingness of participant to provide informed consent to participation.\n\nEXCLUSION CRITERIA:\n\n* Active symptomatic major organ disorder that would increase the risk of biopsy, including but not limited to ischemic heart disease, recent myocardial infarction, active congestive heart failure, pulmonary dysfunction.\n* Pregnant women.\n* Active concomitant medical or psychological illnesses that may increase the risk to the participant or in adult participants, inability to obtain informed consent, at the discretion of the principal investigator.","2 Years","100 Years",{"count":51,"type":21},1000,"OBSERVATIONAL","Background:\n\n* Malignant mesothelioma is a malignancy arising from the mesothelial cells of the pleura, peritoneum, pericardium, or tunica vaginalis.\n* Mesothelioma accounts for 0.10% of deaths annually in the United States. Malignant pleural mesothelioma is the most common of these, comprising of 80% of the cases with an annual incidence of about 2,500 in the United States.\n* The median survival from diagnosis of pleural mesothelioma is approximately 12 months. The majority of patients present with stage III or IV disease with 85-90% of patients considered unresectable at diagnosis.\n* Peritoneal mesothelioma has a better prognosis than pleural mesothelioma; nevertheless, patients undergoing therapy for peritoneal mesothelioma have few well-studied treatment options due in large part to the rarity of the disease.\n* In addition to mesothelioma, mesothelin is highly expressed in several cancers, including pancreatic, biliary adenocarcinomas, gastric and ovarian cancers; mesothelin is also expressed in a significantly larger proportion of thymic carcinoma than thymoma.\n\nObjectives:\n\n-To allow sample acquisition for use in the study of mesothelioma.\n\nEligibility:\n\n* All participants age greater than or equal to 2 years with malignant mesothelioma OR\n* All participants greater than or equal to 18 years with thymic carcinoma, pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers or other solid tumor known to express mesothelin\n* Must be able and willing to provide informed consent if 18 or over; parent or guardian must be able and willing to provide consent for patients under the age of 18\n\nDesign:\n\n* Up to 1000 subjects will be enrolled.\n* Patients will be followed to determine the course of disease and to record any treatment received for mesothelioma.\n* Patients will undergo sampling of blood, urine, tumor and abnormal body fluids for tissue banking.\n* Studies which may be performed on banked material include genetic and genomic studies, establishment of cell cultures and immunologic studies.",[55,27,56,57,58,59],"Thymoma","Pancreatic Neoplasms","Mesothelioma","Biliary Tract Neoplasms","Mesothelin Expressing Neoplasms",[61,62,63,64,65],"Samples","Biobank","Lung Neoplasms","Ovarian Neoplasms","Natural History","2026-06-24",{"date":68,"type":32},"2026-06-25",{"date":70,"type":32},"2013-09-09",{"name":72,"class":73},"National Cancer Institute (NCI)","NIH",{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":40},"100644201","one-click-autofocus-versus-segmented-focus-in-gastric-endoscopy-100644201","NCT07664813","One-Click Autofocus Versus Segmented Focus in Gastric Endoscopy","A Comparative Study of One-Click Autofocus Versus Segmented Focus Techniques Under Magnifying Endoscopy for Gastric Diseases: A Tandem Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients with gastric diseases (e.g., suspicious lesions, known gastric disorders) requiring further magnifying endoscopy examination\n* Ability to understand and provide written informed consent voluntarily\n\nExclusion Criteria:\n\n* Absolute contraindications to upper gastrointestinal endoscopy (e.g., severe cardiopulmonary insufficiency, coagulopathy)\n* Pregnant or lactating women\n* History of gastric surgery (e.g., gastrectomy) that may affect endoscopic manipulation or anatomy","18 Years",{"count":83,"type":21},93,[85],"NA","Magnifying endoscopy provides high-resolution images that enhance the detection of early gastrointestinal lesions. However, conventional manual zoom techniques require frequent focal adjustments, which can be technically demanding and may compromise image stability, especially in complex anatomical settings.\n\nThis study evaluates a novel one-click autofocus system based on image recognition and computer vision algorithms. The system automatically adjusts focal distance within seconds, eliminating the need for manual operation. This trial aims to compare the efficiency and image quality of one-click autofocus versus segmented manual focus in patients undergoing magnifying endoscopy for gastric diseases.\n\nA tandem randomized controlled trial will be conducted to assess procedure time, image clarity score, and operator satisfaction between the two techniques.",[27,88],"Stomach Diseases",[90,91,92,93,94],"Magnifying Endoscopy","Gastroscopy","One-Click Autofocus","Segmented Focus","Image Quality","NOT_YET_RECRUITING","2026-06-23",{"date":66,"type":32},{"date":99,"type":21},"2026-06-18",{"date":101,"type":21},"2026-08-15",{"name":103,"class":39},"Shandong University",{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":116,"conditions":117,"keywords":124,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":135},"100601754","phase-1-a-study-of-ly4257496-in-participants-with-cancer-omniray-100601754","NCT07114601","A Study of LY4257496 in Participants With Cancer (OMNIRAY)","A Phase 1a\u002Fb Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults With GRPR-Positive Advanced Solid Tumors (OMNIRAY)","OMNIRAY","Inclusion Criteria:\n\n* Must have histologically or cytologically proven diagnosis of locally advanced, unresectable, or metastatic cancer.\n* Must be assessed by computed tomography (CT)\u002Fmagnetic resonance imaging (MRI) to confirm at least 1 of the following:\n\n * At least 1 measurable target lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\n * If only bone lesions are present without a soft-tissue component, a bone scan or MRI must confirm at least 2 detectable lesions considered to represent active metastases\n* Must have GRPR-positive disease, defined by investigator assessment of GRPR imaging.\n* Must have the following histologically or cytologically confirmed diagnosis:\n\n * Estrogen receptor (ER+)\u002Fhuman epidermal growth factor receptor 2 (HER2-) breast cancer\n * ER+\u002FHER2+ breast cancer\n * Esophageal squamous cell carcinoma\n * Adenocarcinoma of the stomach, gastroesophageal junction, or esophagus\n * Colorectal carcinoma\n * Metastatic castration-resistant prostate cancer\n * Endometrial carcinoma. Carcinosarcoma is eligible. Uterine leiomyosarcoma, adenosarcoma, or endometrial stromal sarcoma is not eligible.\n * Low-grade papillary serous ovarian cancer\n * Other non-Central Nervous System (CNS) primary GRPR-positive solid tumors (Cohorts A1 dose escalation and D1 dose expansion only)\n* For participants with breast cancer diagnosis, where possible, ER and HER2 status should be assessed from the most recent tissue biopsy taken at the time of presentation with recurrent or metastatic disease.\n\n * To fulfill the requirement for ER+ disease by local testing, a tumor must express the ER immunohistochemistry, as defined in the relevant American Society of Clinical Oncology (ASCO)\u002FCollege of American Pathologists (CAP) guidelines.\n * HER2 status should be determined by local testing, as defined in the relevant ASCO\u002FCAP Guidelines.\n* Must have an Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 1.\n* Must be able to comply with outpatient treatment, laboratory monitoring, imaging, and required clinic visits for the duration of trial participation.\n\nExclusion Criteria:\n\n* Phase 1a (Cohort A1 and A2) only: Previously received radiopharmaceutical or radioligand therapy. For participants with prostate cancer, prior ¹⁷⁷Lu-prostate-specific membrane antigen (PSMA) is permitted.\n* Has a history of ongoing acute pancreatitis within 1 year of screening.\n* Previously received any prior hemi-body or whole-body radiotherapy, or prior external beam radiation therapy (EBRT) to greater than 25% of the bone marrow.\n* A bone superscan, defined as a bone scan that demonstrates markedly increased skeletal radioisotope uptake relative to soft tissues in association with absent or faint genitourinary tract activity.\n* Has evidence of ongoing and untreated urinary tract obstruction or unmanageable urinary incontinence.\n* Have known active hepatitis B virus (HBV). Exception: Individuals with chronic HBV if they:\n\n * Have positive HBsAg\n * Are on suppressive antiviral therapy, as allowed per local regulations prior to C1D1\n * Remain on the same antiviral treatment throughout study, and should follow local standards for continuation of therapy after completion of trial therapy.\n * Have undetectable HBV DNA ≤14 days of C1D1.\n* Have known active hepatitis C virus (HCV). Exception: Individuals previously treated for HCV if they:\n\n * Completed curative antiviral therapy.\n * Have an HCV viral load below the limit of quantification ≤14 days of C1D1 and.\n * Are positive for anti-HCV antibodies and negative for HCV ribonucleic acid (RNA) before randomization.\n* Have untreated human immunodeficiency virus (HIV) infection. Exception: Individuals who have well-controlled HIV infection\u002Fdisease and they:\n\n * Are on a stable and permitted antiretroviral therapy (ART) regimen without changes in drug or dose, for at least 4 weeks prior to C1D1\n * Have a viral load of \\\u003C400 copies\u002FmL ≤14 days of C1D1.\n * Have a CD4+ T-cell count ≥350 cells\u002FmL ≤14 days of C1D1.\n * Have not had an opportunistic infection within the past 12 months.\n* Has an active second malignancy unless in remission with life expectancy greater than 2 years.\n* Has known hypersensitivity to any component or excipient of LY4257496.",{"count":113,"type":21},421,[115],"PHASE1","The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced cancer, including but not limited to breast, colorectal, prostate, endometrial, esophageal, gastroesophageal (GE) junction, and gastric cancer. The study will also evaluate the safety, tolerability, and efficacy of LY4257529 to identify cancer with high levels of a protein called GRPR. This is a 2-part study. Participation could last up to 36 weeks or until your tumor progresses.",[118,119,120,121,122,27,123],"Breast Neoplasms","Colorectal Neoplasms","Prostate Neoplasm","Endometrial Neoplasms","Neoplasm Metastasis","Esophageal Neoplasms",[125],"GRPR-positive","2026-06-19",{"date":96,"type":32},{"date":129,"type":32},"2025-08-06",{"date":131,"type":21},"2035-04",{"name":133,"class":134},"Eli Lilly and Company","INDUSTRY",32,{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":151,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":40},"100584158","phase-1-anti-mesothelin-tnaivescm-hyp218-tnhyp218-car-t-cells-in-participants-with-mesothelin-expressing-solid-tumors-including-mesothelioma-100584158","NCT06885697","Anti-Mesothelin TNaive\u002FSCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma","Phase 1 Study With Dose Expansion of the Anti-Mesothelin TNaive\u002FSCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria. For this protocol, treatment initiation is defined as the first day of lymphodepleting chemotherapy.\n\n* Participant must have unresectable, locally advanced, or metastatic, or recurrent mesothelioma and other mesothelin expressing solid tumors. For participants with mesothelioma only those with epithelioid or biphasic histology (with \\>80% epithelioid component) will be eligible. The diagnosis will be confirmed by the Laboratory of Pathology, CCR, NCI.\n* Participant must have progressed on at least one FDA-approved systemic therapy considered standard of care for their tumor type. There is no limit on the number of prior treatment regimens. Note: Given the aggressive nature of pancreatic cancer, otherwise eligible individuals with this cancer type can undergo leukapheresis before or while they are getting their frontline treatment as long as they meet all other inclusion criteria. However, TNhYP218 CAR T cells will only be administered after progression on first line standard of care therapy.\n* Participant must have at least 1 measurable lesion by RECIST version 1.1.\n* Tumor must have MSLN positivity of 2+ to 3+ in \\>= 50% cancer cells by immunohistochemistry on freshly collected biopsy or archival tissue.\n* Age \\>= 18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Participants must have adequate organ and marrow function as defined below:\n\nSystem: Laboratory Value\n\nHematological\n\n* Hemoglobi: \\>=9 g\u002FdL(a)\n* absolute neutrophil count: \\>=1,500\u002FmcL\n* platelets: \\>=100,000\u002FmcL\n\nHepatic\n\n* total bilirubin: \\\u003C=2.5 X institutional ULN OR direct bilirubin ULN for participants with total bilirubin levels \\>1.5 X ULN\n* AST and ALT \\\u003C= 2.5 X institutional ULN (\\\u003C= 5 X ULN for participants with liver metastases)\n\nRenal\n\n* Creatinine OR: \\\u003C=1.5 X ULN OR\n* Calculated(b) creatinine clearance (GFR can also be used in place of creatinine or CrCl) \\>= 50 mL\u002Fmin for participant with creatinine levels \\> 1.5 X institutional ULN\n\nCoagulation\n\n* International normalized ratio (INR) OR prothrombin time (PT): \\\u003C=1.5 X ULN unless participant is receiving anticoagulant therapy if PT or aPTT is within therapeutic range of intended use of anticoagulants\n* Activated partial thromboplastin time (aPTT): \\\u003C=1.5 X ULN unless participant is receiving anticoagulant therapy if PT or aPTT is within therapeutic range of intended use of anticoagulants\n\nALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase); AST (SGOT)=aspartate aminotransferase (serum glutamic oxaloacetic transaminase); GFR=glomerular filtration rate; ULN=upper limit of normal.\n\n1. Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks.\n2. Creatinine clearance (CrCl) should be calculated per institutional standard.\n\n * Normal cardiac ejection fraction (\\>= 45% by echocardiogram) and no evidence of hemodynamically significant pericardial effusion as determined by an echocardiogram.\n * Room air oxygen saturation of 90% or greater.\n * Treatment-related toxicities from prior treatments must be resolved to \\\u003C= grade 2.\n * Participants with CNS metastases, leptomeningeal disease or carcinomatous meningitis are eligible if they are asymptomatic, have completed their treatment for CNS disease and have recovered from the acute effects of radiation therapy or surgery prior to study entry. Participants must have radiographically stable CNS disease without associated edema at least three months prior to study entry. Additionally, participants have had to have discontinued corticosteroid treatment or non-prophylactic antiseizure medications for these metastases at least four weeks prior to study entry.\n * Participants of child-bearing potential and participants who can father children must agree to use highly effective contraception or abstinence.\n * Participants who are nursing or plan to nurse a child must agree to discontinue\u002Fpostpone nursing for the duration of study therapy and for 12 months after the administration of the cell product or for 4 months from the time no evidence of persistence\u002Fgene modified cells is documented in the participant s blood.\n * Ability of participant to understand and the willingness to sign a written informed consent document.\n\n EXCLUSION CRITERIA:\n\n An individual who meets any of the following criteria will be excluded from participation in this study:\n * Prior systemic therapy, an investigational therapy, radiation, and\u002For surgery within 14 days prior to leukapheresis and 21 days prior to lymphodepleting chemotherapy.\n * Prior administration of anti-PD-1 or anti-PD-L1 antibodies or other agents that in the opinion of the PI can stimulate immune activity and interfere with an infusion of CAR-T cells within 8 weeks prior to treatment initiation.\n * Participants with any form of primary immunodeficiency (e.g. severe combined immunodeficiency).\n * Participants with active or history of autoimmune or immune mediated disease such as multiple sclerosis, lupus, inflammatory bowel disease, rheumatoid arthritis, or small vessel vasculitis. NOTE: Participants with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible.\n * History of severe immediate hypersensitivity reaction to cyclophosphamide or fludarabine.\n * Therapeutic doses of systemic corticosteroid therapy within 14 days prior to treatment initiation. Physiological doses of steroids (up to 5mg\u002Fday of prednisolone or equivalent) are allowed. Corticosteroid creams, ointments, and eye drops are allowed.\n * Participants with lung fibrosis, inflammatory lung disease or evidence of pneumonitis on baseline imaging studies or medical history of these disorders.\n * Participant has any other prior or concurrent malignancy with the following exceptions:\n\n * Adequately treated basal cell or squamous cell carcinoma\n * In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 12 months prior to initiation of study therapy.\n * Treated non-melanoma skin cancer.\n * Stage 0 or 1 melanoma completely resected at least 12 months prior to initiation of study therapy.\n * Successfully treated organ-confined prostate cancer with no evidence of progressive disease based on PSA levels and are not on active therapy.\n * A primary malignancy which has been completely resected and in complete remission for \\>= 5 years.\n * Electrocardiogram showing a QTc interval \\> 450 msec in males and \\> 470 msec in females (\\> 80 msec for participants with bundle branch block). Either Fridericia s or Bazett s formula may be used to correct the QT interval.\n * Participant has active infection with HIV, hepatitis B virus, HCV, or HTLV as defined below:\n\n * Positive serology for HIV, HTLV-1, or HTLV-2.\n * Active hepatitis B infection as demonstrated by test for hepatitis B surface antigen. Participants who are hepatitis B surface antigen negative but are hepatitis B core antibody positive must have undetectable hepatitis B DNA and receive prophylaxis against viral reactivation.\n * Active hepatitis C infection as demonstrated by hepatitis C RNA test. Participants who are HCV antibody positive will be screened for HCV RNA by any reverse transcription PCR or branched DNA assay. If HCV antibody is positive, eligibility will be determined based on a negative screening RNA value.\n * Participant is pregnant or intends to be pregnant during the required period of contraception for participants of childbearing potential.\n * Participants who received live or attenuated vaccine or virus-based vaccine within 30 days before initiation of treatment initiation\n * Participants with a history of seizure disorder unless due to now treated metastatic lesions.\n * Ongoing uncontrolled intercurrent illness, including but not limited to ongoing or active infection, that would impact participant safety or limit compliance with study requirements.","120 Years",{"count":20,"type":21},[115],"Background:\n\nMesothelioma is an aggressive cancer that grows in the linings of the body; this can include the membranes that line the heart, lungs, and internal organs. Mesothelin (MSLN) is a protein that appears in high numbers in many tumors, including mesothelioma. Researchers are developing a new treatment that collects a person s own immune cells (T cells); the T cells are genetically modified to target and kill tumor cells with high levels of MSLN.\n\nObjective:\n\nTo test a new treatment (TNhYP218 CAR T cells) in people with solid tumors including mesothelioma.\n\nEligibility:\n\nPeople aged 18 and older with solid tumors including mesothelioma that returned or spread after standard treatment.\n\nDesign:\n\nParticipants will be screened. A small piece of tissue will be cut from a tumor (biopsy). The sample will be tested to see if it has enough MSLN.\n\nParticipants will undergo leukapheresis: Blood will be taken from their body through a vein. The blood will pass through a machine that separates out the T cells. The remaining blood will be returned to the body through a different vein.\n\nParticipant s T cells will be modified in a lab to produce TNhYP218 CAR T cells.\n\nParticipants will enter the hospital. For 7 days, they will receive drugs to prepare their bodies for the study treatment.\n\nTNhYP218 CAR T cells will be administered into a vein. Participants will remain in the hospital for at least 7 more days.\n\nAfter discharge, participants will have follow-up visits for 5 years. These visits may include imaging scans, blood and heart tests, and a new biopsy.\n\nLong-term follow-up will continue another 10 years....",[57,148,27,56,64,63,149,150],"Neoplasms","Thymus Neoplasms","Colonic Neoplasms",[152,153,154,155,156,157,158,159,160,161],"Peritoneal Mesothelioma","Thymic Carcinoma","Colon Cancer","Gastric Cancer","Lung Cancer","Ovarian Cancer","Pancreatic Cancer","mesothelin expressing solid tumors","CAR T cell therapy","Gene Therapy","2026-06-16",{"date":164,"type":32},"2026-06-17",{"date":166,"type":32},"2025-07-08",{"date":168,"type":21},"2044-06-01",{"name":72,"class":73},{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":180,"briefSummary":181,"conditions":182,"keywords":185,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":198},"100609377","phase-1-a-study-of-ly4337713-in-participants-with-fap-positive-solid-tumors-100609377","NCT07213791","A Study of LY4337713 in Participants With FAP-Positive Solid Tumors","A Dose Escalation and Dose Optimization Phase 1a\u002F1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT)","FiREBOLT","Inclusion Criteria:\n\n* Must have clinical or imaging evidence of fibroblast activation protein (FAP) expression per local assessment\n* Must have histologically or cytologically confirmed diagnosis of one of the following:\n\n * Adenocarcinoma of the pancreas\n * Hormone receptor (HR)-positive human epidermal growth factor 2 (HER2)-negative breast cancer\n * HER2-positive breast cancer\n * Triple negative breast cancer (TNBC)\n * Platinum-resistant or refractory ovarian cancer (including ovarian carcinosarcoma)\n * Other solid tumors\n\n * Gastric cancer (adenocarcinoma)\n * Colorectal cancer (CRC)\n * Esophageal cancer (squamous cell carcinoma or adenocarcinoma)\n * Cholangiocarcinoma\n* Must have received prior treatments as indicated below:\n\n * Phase 1a\n\n * Adenocarcinoma of the pancreas: Participants must have received at least 1, but no more than 2 prior regimens for locally advanced unresectable or metastatic disease.\n * HR-positive HER2-negative breast cancer: Participants must have received less than or equal to (≤)5 prior lines of treatment for advanced or metastatic disease, which must include a cyclin-dependent kinase 4\u002F6 inhibitor.\n * HER2-positive breast cancer: Participants must have received at least 2 lines of HER2-targeted therapy, which should include at least 1 antibody-drug conjugate (ADC) for metastatic disease (if locally available).\n * TNBC: Participants must have received at least 2 lines of therapy for metastatic disease.\n * Platinum-resistant or refractory ovarian cancer: Participants must have received or after at least 1 platinum-based therapy.\n * Other solid tumors (gastric cancer, CRC, esophageal and cholangiocarcinoma): Participants must have received greater than or equal to (≥)1 prior line of systemic therapy for advanced or metastatic disease; including prior line(s) in combination with immunotherapy or vascular endothelial growth factor inhibitor.\n * Phase 1b:\n\n * Participants must have advanced or metastatic solid tumors and have received ≥1 prior line of therapy.\n* Must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1.\n* Measured creatinine clearance ≥60 milliliters per minute (mL\u002Fmin)\n\nExclusion Criteria:\n\n* Have known active central nervous system (CNS) metastases or carcinomatous meningitis.\n* Have significant cardiovascular disease\n* Have prolongation of the corrected QTcF \\>470 milliseconds (msec) during screening. QTcF is calculated using Fridericia's Formula: QTcF = QT\u002F(RR0.33)\n* Have evidence of ongoing and untreated urinary tract obstruction\n* Had previous hemi- or total-body radiation.\n* Had previous adoptive T-cell therapy (e.g., chimeric antigen receptor T-cell \\[CAR-T therapy, T-cell receptor \\[TCR\\] therapy, etc.)\n* Unable to lie flat during, or otherwise tolerate, single photon emission computed tomography (SPECT), positron emission tomography (PET), computed tomography (CT) or magnetic resonance imaging (MRI).",{"count":179,"type":21},241,[115],"This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.",[64,118,183,119,123,27,184],"Pancreatic Intraductal Neoplasms","Cholangiocarcinoma",[186,187,188,189],"Cancer-associated fibroblasts (CAF)","Lutetium-177","LuFAP","Lu-177-FAP","2026-06-03",{"date":192,"type":32},"2026-06-04",{"date":194,"type":32},"2025-10-22",{"date":196,"type":21},"2033-03",{"name":133,"class":134},30,{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":206,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":209,"briefSummary":211,"conditions":212,"keywords":214,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":225},"100554872","phase-2-to-evaluate-iah0968-in-combination-with-capeox-in-her2-positive-gastric-cancer-100554872","NCT06504732","To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer","A Phase II\u002FIII Clinical Study Evaluating IAH0968 in Combination or Not in Combination With the CAPEOX Regimen in HER2-expressing Advanced\u002FMetastatic Solid Tumors and Gastric Cancer","Inclusion Criteria:\n\n* 1\\) Age 18\\~75 years old (including critical mass), gender is not limited. 2) Phase II cohort 1 only: patients with locally advanced or metastatic gastric cancer (including adenocarcinoma of the gastro-esophageal junction) diagnosed by histopathology, unsuitable for radical surgical resection or localized treatment, and who have not received systemic antitumor therapy (including systemic chemotherapy, molecularly-targeted drug therapy, biologic therapy, and other investigational therapeutic agents) for GC (except for adjuvant chemotherapy for \\>6 months), and who have demonstrated disease progression; and patients who have been diagnosed by immunohistochemistry (IHC) staining and\u002For fluorescence in situ hybridization (FISH). and demonstrated disease progression excepted); HER2 positivity (IHC 3+, or IHC 2+ and FISH +) demonstrated by immunohistochemical (IHC) staining and\u002For fluorescence in situ hybridization (FISH).\n\n 3\\) Phase II Cohort 2 only: Have histologically or cytologically confirmed advanced malignant solid tumors that have failed standard treatment, or for which no standard treatment options are available, or for which standard treatment is not applicable at this stage; and are HER2 underexpressed (IHC 2+ and FISH-, or IHC 1+) as evidenced by immunohistochemistry (IHC) staining and\u002For fluorescence in situ hybridization (FISH).\n\n 4\\) Phase II Cohort 3 only: with locally advanced or metastatic gastric cancer (including gastro-oesophageal junction adenocarcinoma) or colorectal cancer diagnosed by histopathology, unsuitable for radical surgical resection or localized treatment, with no prior systemic (including systemic chemotherapy, molecularly-targeted drug therapy, biologic therapy, and other investigational therapeutic agents) antitumor therapy (having received adjuvant chemotherapy for \\>6 months with evidence of disease progression), patients with wild-type KRAS, NRAS, and BRAF genes (mCRC only); and HER2 low expression (IHC 2+ and FISH-, or IHC 1+) demonstrated by immunohistochemical (IHC) staining and\u002For fluorescence in situ hybridization (FISH).\n\n 5\\) At least 1 measurable lesion according to RECIST 1.1 criteria (tumor lesions located in the area of prior radiotherapy or other localized regional treatment sites are generally not considered measurable lesions unless the lesion shows definite progression or persists after three months of radiotherapy).\n\n 6\\) Eastern Cooperative Oncology Group (ECOG) physical status score of 0 to 1. 7) Have an expected survival of ≥ 3 months. 8) Adequate organ function:\n\n ① Hematologic system (no transfusion or hematopoietic stimulating factor therapy within 14 days): absolute neutrophil count (ANC) ≥ 1.5 × 109\u002FL, platelet count (PLT) ≥ 90 × 109\u002FL, hemoglobin (HGB) ≥ 90 g\u002FL; Liver function: total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN), except Gilbert's syndrome; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 times the ULN, liver metastasis or hepatocellular carcinoma patients need to AST and ALT ≤ 5.0 times the ULN and total bilirubin ≤ 3.0 times the ULN; Renal function: serum creatinine (Cr) ≤1.5 times ULN; if creatinine \\>1.5 times ULN, creatinine clearance (Ccr) ≥50 mL\u002Fmin (calculated according to Cockcroft-Gault formula);\n\n ④ Coagulation function: International Normalized Ratio (INR) ≤ 1.5 times ULN for prothrombinogen, Activated Partial Thromboplastin Time (APTT) ≤ 1.5 times ULN, or INR and APTT ≤ 2.5 times ULN for patients with liver metastasis or hepatocellular carcinoma.\n\n 9\\) Eligible patients (male and female) of childbearing potential must agree to use a reliable method of contraception (hormonal or barrier method or abstinence) with their partner for the duration of the trial and for at least 6 months after the last dose; female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose of study drug.\n\n 10\\) Subjects must give informed consent for this study prior to the trial and voluntarily sign a written informed consent form.\n\n 11)Phase III only: Patients with histologically confirmed locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma), who have received no prior systemic anti-tumor therapy for gastric carcinoma (GC), including systemic chemotherapy, molecular targeted therapy, biotherapy and other investigational medicinal products. One cycle of 5-FU-based chemotherapy is permitted; patients who received neoadjuvant\u002Fadjuvant chemotherapy completed ≥6 months previously with documented disease progression are also eligible. HER2 positivity shall be confirmed via immunohistochemistry (IHC) and\u002For fluorescence in situ hybridization (FISH): defined as IHC 3+, or IHC 2+ with positive FISH result. PD-L1 expression testing on primary or metastatic tumor tissue samples confirms a PD-L1 CPS score \\\u003C1.\n\nExclusion Criteria:\n\n* 1\\) Phase II Cohort 2 only: received antitumor therapy such as chemotherapy, radiotherapy, biologic therapy, endocrine therapy, immunotherapy, etc. within 4 weeks prior to the first use of study drug, except for the following:\n\n * Nitrosourea or mitomycin C within 6 weeks prior to first use of study drug;\n\n * Oral fluorouracil analogs and small molecule targeted drugs for 2 weeks prior to the first use of the study drug or within 5 half-lives of the drug (whichever is longer);\n\n * Within 2 weeks prior to first use of the study drug for proprietary Chinese medicines with antitumor indications.\n\n 2\\) Received other unlisted clinical investigational drug or therapy within 4 weeks prior to first use of the study drug.\n\n 3\\) Adverse effects of prior antineoplastic therapy have not returned to NCI CTCAE 5.0 grade rating of ≤ grade 1 or relevant provisions of the enrollment criteria (except for toxicities judged by the investigator to pose no safety risk, such as alopecia, grade 2 peripheral neurotoxicity, and hypothyroidism stabilized by hormone replacement therapy).\n\n 4\\) Known hypersensitivity to any antibody-based drug (NCI CTCAE 5.0 grade rating ≥ 3) or hypersensitivity to the study drug and the active ingredient or inactive excipients of the CAPEOX regimen.\n\n 5\\) Diagnosed defective mismatch repair (dMMR) or high microsatellite instability (MSI-H) solid tumor (except unknown MSI\u002FMMR status).\n\n 6\\) Major surgical procedure (excluding puncture biopsy), major trauma within 4 weeks prior to first use of study drug, or need for elective surgery during the trial.\n\n 7\\) Received systemic glucocorticosteroids (prednisone \\> 10 mg\u002Fday or equivalent) within 14 days prior to the first dose of study drug, except for the following: treatment with topical, ocular, intra-articular, intranasal, and inhaled glucocorticosteroids; and short-term prophylactic glucocorticosteroids (e.g., for prevention of allergy to contrast media).\n\n 8\\) Other immunosuppressive therapy within 28 days or 5 half-lives (whichever is longer) prior to first use of study drug.\n\n 9\\) Use of immunomodulatory drugs within 14 days prior to first use of study drug.\n\n 10\\) Use of any live vaccine within 4 weeks prior to the first dose of study drug.\n\n 11\\) Previous allogeneic hematopoietic stem cell transplantation or organ transplantation.\n\n 12\\) Parenchymal brain metastases or meningeal metastases with clinical symptoms.\n\n 13\\) Have an active infection that currently requires intravenous anti-infective therapy.\n\n 14\\) Have a history of immunodeficiency, including a positive antibody test for human immunodeficiency virus (HIV).\n\n 15\\) Have active hepatitis B (HBsAg positive and HBV-DNA positive or greater than the upper limit of normal) and active hepatitis C (hepatitis C virus antibody positive and HCV RNA positive or greater than the upper limit of normal).\n\n 16\\) Have severe and uncontrollable lung disease (severe infectious pneumonia, interstitial lung disease, etc.).\n\n 17\\) Have a history of severe cardiovascular disease, including but not limited to:\n * Having severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, degree II-III atrioventricular block;\n\n * Mean QT interval (QTcF) corrected by the Fridericia method \\> 470 ms;\n\n * Acute coronary syndrome, congestive heart failure, aortic coarctation, stroke, or other grade 3 or higher cardiovascular event within 6 months prior to the first dose;\n\n ④ Presence of New York Heart Association (NYHA) Cardiac Function Class ≥ Grade II heart failure or left ventricular ejection fraction (LVEF) \\\u003C 50%, or other structural heart disease judged by the investigator to be of high risk;\n\n ⑤ Clinically uncontrolled hypertension. 18) Active, or previous autoimmune disease with potential for relapse (e.g., systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.), except for clinically stable autoimmune thyroid disease, type I diabetes mellitus, vitiligo, cured atopic dermatitis in children, and psoriasis that does not require systemic therapy (within the past 2 years).\n\n 19\\) Presence of other malignancies within 5 years prior to the start of study dosing, except: malignancies for which cure can be expected with treatment (including, but not limited to, adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or ductal carcinoma in situ of the breast treated by radical surgery).\n\n 20\\) Presence of clinically uncontrollable third interstitial fluid that, in the judgment of the Investigator, makes enrollment inappropriate.\n\n 21\\) Known alcohol or drug dependence. 22) Have a mental disorder or poor compliance. 23) Pregnant or lactating females. 24) In the opinion of the investigator, the subject has a history of other serious systemic disease or is otherwise unsuitable for enrollment in this clinical study.","75 Years",{"count":208,"type":21},574,[24,210],"PHASE3","The safety, tolerability, and determination of the maximum tolerated dose (MTD) of the combination therapy were first evaluated for IAH0968 in combination with or without the CAPEOX regimen in unsystematically treated subjects with HER2-expressing advanced\u002Fmetastatic colorectal or gastric cancers (including adenocarcinomas of the gastro-esophageal junction) or HER2-hypo-expressing advanced\u002Fmetastatic solid tumors. The efficacy of IAH0968 in combination with the CAPEOX regimen versus trastuzumab in combination with the CAPEOX regimen in subjects with HER2-positive advanced\u002Fmetastatic gastric cancer, including gastro-esophageal junction adenocarcinoma, was then assessed by progression-free survival (PFS) and OS according to the Research and Evaluation Criteria for the Evaluation of Efficacy in Solid Tumors (RECIST) 1.1.",[27,213],"Solid Tumor",[215,216],"gastric cancer","HER2-positive",{"date":218,"type":32},"2026-06-05",{"date":220,"type":32},"2024-08-15",{"date":222,"type":21},"2029-07",{"name":224,"class":134},"SUNHO（China）BioPharmaceutical CO., Ltd.",2,{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":233,"targetDuration":4,"studyType":22,"phases":235,"briefSummary":236,"conditions":237,"keywords":241,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":40},"100637792","pulsar-combined-with-immunotherapy-for-unresectable-locally-advanced-gastric-cancer-100637792","NCT07607119","PULSAR Combined With Immunotherapy for Unresectable Locally Advanced Gastric Cancer","A Prospective Phase II Study of Systemic Therapy With Immunotherapy Combined With Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy (PULSAR) in Unresectable Locally Advanced Gastric Cancer","Inclusion Criteria:\n\nAge 19 or more years. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. Histologically confirmed gastric adenocarcinoma. Tumor biomarker status: HER-2 negative, EBV negative, and Microsatellite Stable (MSS).\n\nUnresectable, locally advanced extent at initial staging (Para-aortic lymph node \\[PALN\\] and Supraclavicular lymph node \\[SCN\\] metastases are allowed).\n\nHas completed 3 or more cycles of first-line systemic therapy combined with immunotherapy without evidence of disease progression.\n\nPresence of at least one evaluable lesion according to RECIST v1.1 that is deemed safely irradiable by the investigator.\n\nVoluntary written informed consent provided by the subject.\n\nExclusion Criteria:\n\nPregnant or lactating women. Presence of brain metastases or leptomeningeal involvement. Prior history of radiation therapy to the intended target site. Severe uncontrolled comorbidities that, in the investigator's opinion, limit study participation or treatment compliance (e.g., uncontrolled infection, heart failure, arrhythmia, psychiatric illness).\n\nInability or unwillingness to comply with the study protocol procedures. Any condition deemed inappropriate for study participation by the principal investigator or attending physician.",{"count":234,"type":21},53,[85],"The purpose of this prospective, single-center, phase II study is to evaluate the clinical efficacy and safety of combining first-line systemic therapy plus immunotherapy with personalized ultrafractionated stereotactic adaptive radiation therapy (PULSAR) in patients with unresectable locally advanced gastric cancer.",[238,27,239,240],"Gastric Adenocarcinoma","Locally Advanced Gastric Cancer","Unresectable Gastric Cancer",[242,243],"HER2-negative Stomach Cancer","Microsatellite Stable Gastric Cancer","2026-05-24",{"date":246,"type":32},"2026-05-28",{"date":248,"type":32},"2026-05-15",{"date":250,"type":21},"2030-04-30",{"name":252,"class":39},"Samsung Medical Center",{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":40},"100640321","single-port-versus-conventional-laparoscopic-surgery-for-radical-proximal-gastric-cancer-a-randomized-controlled-trial-100640321","NCT07586384","Single-port Versus Conventional Laparoscopic Surgery for Radical Proximal Gastric Cancer: A Randomized Controlled Trial","A Prospective, Single-center, Randomized Control Led Study of Laparoscopic Single-port Surgery System Versus Traditional Laparoscopic Surgery in Radical Proximal Gastric Cancer","Inclusion Criteria:\n\n* Age between 18 and 75 years inclusive.\n\nECOG performance status ≤ 2.\n\nHistologically confirmed proximal gastric cancer or Siewert type II adenocarcinoma of the esophagogastric junction.\n\nClinical stage cT1-T3, N0-N+, M0.\n\nTumor maximum diameter ≤ 4 cm and esophageal invasion ≤ 2 cm.\n\nCandidates for radical proximal gastrectomy (PG) with feasibility of R0 resection and functional anastomosis.\n\nAssessed by a Multidisciplinary Team (MDT) as suitable for PG rather than total gastrectomy, with no requirement for neoadjuvant therapy.\n\nRadiographic evidence of localized disease (no distant metastasis to liver, lung, or peritoneum via enhanced CT or MRI).\n\nASA physical status classification ≤ III.\n\nAdequate bone marrow, hepatic, renal, cardiac, and pulmonary function.\n\nAbility to understand and provide written informed consent.\n\nWillingness and ability to comply with the 12-month postoperative follow-up schedule.\n\nExclusion Criteria:\n\n* Clinical stage T4 or presence of distant metastasis.\n\nEsophageal invasion exceeding 2 cm.\n\nHistory of previous major gastric surgery (e.g., partial or total gastrectomy).\n\nOther malignant tumors within the last 5 years.\n\nSevere organic diseases that preclude safe anesthesia or surgery (e.g., severe heart failure, pulmonary fibrosis).\n\nRequirement for emergency surgery due to active gastric bleeding, perforation, or acute obstruction.\n\nPregnant or lactating women.\n\nSerious psychiatric disorders or cognitive impairment that interferes with study compliance.\n\nAny other condition that, in the opinion of the investigator, would make the participant unsuitable for the study.","80 Years",{"count":262,"type":21},90,[85],"To evaluate the safety and efficacy of SP1000 and conventional laparoscopy in radical gastrectomy for proximal gastric cancer.",[27,266],"Robotic Surgical Procedures","2026-05-08",{"date":269,"type":32},"2026-05-14",{"date":271,"type":32},"2025-11-05",{"date":273,"type":21},"2027-09-30",{"name":275,"class":39},"First Affiliated Hospital of Wenzhou Medical University",{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":22,"phases":285,"briefSummary":286,"conditions":287,"keywords":298,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":322},"100392410","phase-1-a-study-of-sigvotatug-vedotin-in-advanced-solid-tumors-100392410","NCT04389632","A Study of Sigvotatug Vedotin in Advanced Solid Tumors","A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors","Inclusion Criteria:\n\n* Disease indication\n\n * Participants must have histologically or cytologically confirmed metastatic or unresectable solid malignancy within one of the tumor types listed below (dependent on study part).\n\n * Non-small cell lung cancer (NSCLC)\n * Head and neck squamous cell cancer (HNSCC)\n * Advanced HER2-negative breast cancer\n * Esophageal squamous cell carcinoma (ESCC)\n * Esophageal\u002FGastro-esophageal junction adenocarcinoma (EAC\u002FGEJ)\n * Cutaneous squamous cell cancer (cSCC)\n * Exocrine pancreatic adenocarcinoma\n * Bladder cancer\n * Cervical cancer\n * Gastric cancer\n * High grade serous ovarian cancer (HGSOC)\n * Part A only: Participants must have disease that is relapsed or refractory or be intolerant to standard-of-care therapies and should have no appropriate standard-of-care therapeutic options.\n * Part B only: Participants must have disease that is relapsed or refractory or be intolerant to standard-of-care therapies. Participants must have received platinum-based therapy and a PD-1\u002FPD-(L)1 inhibitor, if applicable and available.\n * Part C only: For pembrolizumab combination cohorts, participants must be eligible for pembrolizumab per local standard of care. For pembrolizumab with cisplatin or carboplatin, participants must be eligible for both pembrolizumab and the platinum agent per local standard of care. Participants must be treatment naïve for locally advanced or metastatic systemic therapy (prior definitively intended or \\[neo\\]adjuvant therapy is allowed).\n * Part D only: Participants must be treatment naïve for locally advanced or metastatic systemic therapy.\n* Participants enrolled in the following study parts should have a tumor site accessible for biopsy and agree to biopsy as follows:\n\n * Disease-specific expansion cohorts (Part B and Part D): A baseline fresh tumor biopsy is required. An archival biopsy collected within 90 days prior to first dose of study drug may be used.\n * Biology expansion cohort: pretreatment biopsy and on-treatment (Cycle 1) biopsy\n* An Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Measurable disease per the RECIST v1.1 at baseline\n\nExclusion Criteria\n\n* History of another malignancy within 3 years before first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.\n* Known active central nervous system metastases. Participants with previously treated brain metastases may participate provided they:\n\n * are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment,\n * have no new or enlarging brain metastases, and\n * are off of corticosteroids prescribed for symptoms associated with brain metastases for at least 7 days prior to first dose of study drug.\n * In Part D, participants with untreated, asymptomatic CNS metastases smaller than 1 cm may be enrolled without definitive treatment as long as they have no neurological symptoms, no or minimal surrounding edema, and no requirements for corticosteroids.\n* Carcinomatous meningitis\n* Previous receipt of an MMAE-containing agent or an agent targeting integrin beta-6\n* Pre-existing neuropathy Grade 1 or greater per the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0) for Parts C and D cohorts with cisplatin or carboplatin; Grade 2 or greater per the NCI CTCAE v5.0 for all other cohorts\n* Any uncontrolled Grade 3 or higher (per NCI CTCAE v5.0) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of sigvotatug vedotin.\n\n * Routine antimicrobial prophylaxis is permitted\n* Grade ≥3 pulmonary disease unrelated to underlying malignancy. This includes clinically severe pulmonary function compromise resulting from clinically significant pulmonary illnesses\n* Part C and D: Prior therapy with a PD-1 inhibitor, anti-PD-(L)1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor and was discontinued from that treatment due to a Grade 3 or higher immune-mediated adverse event (IMAE).\n* History of noninfectious interstitial lung disease (ILD) or pneumonitis that required steroids, current ILD or pneumonitis, or suspected ILD or pneumonitis that cannot be ruled out by imaging at screening\n* Known diffusing capacity of the lung for carbon monoxide (DLCO; adjusted for hemoglobin) \\\u003C50% predicted\n* Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.",{"count":284,"type":21},1006,[115],"This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether sigvotatug vedotin works to treat solid tumors.\n\nThe study will have four parts.\n\n* Part A of the study will find out how much sigvotatug vedotin should be given to participants.\n* Part B will use the dose found in Part A to find out how safe sigvotatug vedotin is and if it works to treat solid tumors.\n* Part C of the study will find out how safe sigvotatug vedotin is in combination with these other drugs.\n* Part D will include people who have not received treatment. This part of the study will find out how safe sigvotatug vedotin is in combination with these other drugs and if these combinations work to treat solid tumors.\n* In Parts C and D, participants will receive sigvotatug vedotin with either:\n\n * Pembrolizumab or,\n * Pembrolizumab and carboplatin, or\n * Pembrolizumab and cisplatin.",[288,289,290,291,292,293,64,294,295,296,297,27],"Carcinoma, Non-Small Cell Lung","Squamous Cell Carcinoma of Head and Neck","HER2 Negative Breast Neoplasms","Esophageal Squamous Cell Carcinoma","Esophageal Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Cutaneous Squamous Cell Cancer","Exocrine Pancreatic Adenocarcinoma","Urinary Bladder Neoplasms","Uterine Cervical Neoplasms",[299,300,301,302,303,304,305,306,307,308,309,310,311,312,155,313],"NSCLC","HNSCC","cSCC","ESCC","EAC","GEJ","HGSOC","Advanced HER2-Negative Breast Cancer","High Grade Serous Ovarian Cancer","Non-Small Cell Lung Cancer","Head and Neck Squamous Cell Cancer","Esophageal Cancer","Bladder Cancer","Cervical Cancer","Seattle Genetics",{"date":315,"type":32},"2026-05-11",{"date":317,"type":32},"2020-06-08",{"date":319,"type":21},"2029-03-22",{"name":321,"class":134},"Seagen, a wholly owned subsidiary of Pfizer",159,{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":206,"enrollmentInfo":330,"targetDuration":4,"studyType":22,"phases":332,"briefSummary":333,"conditions":334,"keywords":335,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":40},"100593495","phase-2-conversion-therapy-plus-surgery-and-radiotherapy-for-retroperitoneal-nodal-metastases-in-gastric-cancer-100593495","NCT07007182","Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer","A Randomized, Controlled, Multicenter Phase II Study of Conversion Therapy Combined With Surgery and Radiotherapy for Retroperitoneal Lymph Node Metastases in Gastric Cancer","Inclusion:\n\nHistologically confirmed gastric adenocarcinoma with isolated para-aortic (station 16) lymph node metastasis; pMMR or MSS subtype; ECOG performance status 0-2; Life expectancy ≥ 3 months; Adequate organ function (hematologic, hepatic, renal); Ability to provide tumor tissue for biomarker analysis; Ability to understand and willingness to sign written informed consent; Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during study and for 12 months after treatment; men with partners of childbearing potential must also agree to contraception.\n\nExclusion Criteria:\n\nEvidence of visceral or peritoneal metastasis; MSI-H or dMMR subtype; HER2-positive disease (IHC 3+ or IHC 2+ with FISH positive); Prior systemic anti-tumor therapy; Prior malignancy within 3 years (except adequately treated basal cell\u002Fsquamous cell carcinoma of the skin or in situ carcinoma); Prior PD-1\u002FPD-L1\u002FCTLA-4 therapy; Participation in another interventional trial within 4 weeks; Active autoimmune disease requiring systemic therapy within past 2 years; Uncontrolled infection, hepatitis B, C, or HIV; CNS metastases or carcinomatous meningitis; Uncontrolled cardiovascular disease (unstable angina, recent MI, NYHA III-IV heart failure, QTc ≥480 ms); Interstitial lung disease or uncontrolled pulmonary disease; Uncontrolled diabetes mellitus (FBG \\>10 mmol\u002FL); Pregnancy or breastfeeding; Major surgery within 4 weeks prior to randomization; Any other condition that may interfere with protocol compliance or increase risk as judged by the investigator.",{"count":331,"type":21},54,[24],"This is a randomized, controlled, multicenter phase II clinical trial evaluating the efficacy and safety of conversion therapy combined with radical gastrectomy and adjuvant radiotherapy targeting para-aortic (station 16) lymph nodes in patients with gastric adenocarcinoma and isolated station 16 nodal metastases. Eligible participants must have no evidence of peritoneal dissemination, visceral metastases, or non-regional lymphatic spread. Based on PD-L1 combined positive score (CPS), patients in the experimental arm will receive systemic therapy with SOX (S-1 plus oxaliplatin) with or without a PD-1 inhibitor, followed by D2 gastrectomy and postoperative adjuvant SOX chemotherapy, then intensity-modulated radiotherapy (IMRT) to the para-aortic region. The control arm will receive standard chemotherapy with CAPEOX or SOX, with or without immunotherapy, according to CPS status. The primary endpoint is progression-free survival (PFS), with secondary endpoints including overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety. This study aims to explore whether the addition of locoregional treatment to systemic therapy improves long-term outcomes in this select patient population.",[238,27],[336,337,338,339,340,341],"Conversion therapy","Para-aortic lymph nodes","D2 gastrectomy","Radiotherapy","SOX regimen","Immunotherapy","2026-04-27",{"date":344,"type":32},"2026-05-01",{"date":346,"type":32},"2025-10-01",{"date":348,"type":21},"2030-10-01",{"name":350,"class":39},"Jinbo Yue",{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":206,"enrollmentInfo":358,"targetDuration":4,"studyType":22,"phases":360,"briefSummary":361,"conditions":362,"keywords":364,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":377},"100560421","phase-2-efficacy-and-safety-of-serplulimab-combined-with-chemotherapy-as-neoadjuvant-treatment-for-locally-advanced-gastric-cancer-or-adenocarcinoma-of-esophagogastric-junction-100560421","NCT06576921","Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction","Efficacy and Safety of Serplulimab Combined With Nab-paclitaxel and SOX as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Age older than 18 and younger than 75 years\n* Primary GC or AEG (Siewert II\u002FIII)confirmed pathologically by endoscopic biopsy\n* Clinical stage T3\u002FT4N+M0 disease as assessed by CT\u002FMRI, PET-CT, and laparoscopy, if feasible\n* At least one measurable lesion according to the RECIST, version 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Surgical treatment after neoadjuvant chemotherapy is planned according to clinical staging criteria.\n* Life expectancy of at least 3 months\n* Acceptable bone marrow, hepatic, and renal function, including: a)Blood routine examination(No blood transfusion within 14 days; No granulocyte colony-stimulating factor (G-CSF) or other hematopoietic stimulating factors were used): white blood cell count ≥3.5 ×109\u002FL, neutrophils ≥1.5 × 109\u002FL, platelet count \\>100 × 109\u002FL, and hemoglobin ≥90 g\u002FL; b)Hepatic function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST), ALT and AST≤2.5×ULN; total bilirubin (TBIL) ≤1.5×ULN (Gilbert syndrome patients, ≤3×ULN); c)Renal function: serum creatinine (Cr) ≤1.5×ULN or creatinine clearance (Ccr) ≥60mL\u002F min; d)Coagulation function: activated partial thromboplastin time (APTT), international standardized ratio (INR), prothrombin time (PT) ≤1.5×ULN;\n* Written informed consent\n\nExclusion Criteria:\n\n* Squamous cell carcinoma, adenosquamous cell carcinoma, small cell carcinoma, and undifferentiated gastric cancer were confirmed by pathology\n* Positive Her-2 detection (IHC3+ or IHC2+ amplified by FISH detection)\n* Prior chemotherapy, radiotherapy, hormone therapy, targeted therapy, or immunotherapy\n* Contraindications for surgical treatment or chemotherapy\n* Presence of distant metastasis\n* History of other malignant disease within the past 5 years, except: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that have been treated radically and have shown no signs of disease for at least 5 years\n* Any active or history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, except for subjects with vitiligo or resolved childhood asthma\u002Fatopy\n* History of immunodeficiency diseases, including human immunodeficiency virus (HIV), or other acquired or congenital immune-deficient disease, or transplantation\n* Severe mental disorder\n* Presence of digestive tract obstruction, jaundice, acute infectious diseases, inflammatory bowel disease, Crohn's disease, ulcerative colitis, chronic diarrhea, active tuberculosis\n* Immunosuppressive drugs are required for 2 weeks or within 2 weeks or during the study period, excluding the following: a) intranasal, inhaled, topical or topical steroid injections (e.g. intra-articular injections); b) Physiological dose of systemic corticosteroids (≤10mg\u002F day prednisone or equivalent dose); c) Short-term (≤7 days) use of steroids for the prevention or treatment of non-autoimmune allergic diseases;\n* Patients who have undergone major surgery or received live virus vaccine within 4 weeks\n* Pregnant or breast-feeding women, subjects who are unwilling to receive effective contraception during treatment and within 6 months after the end of treatment (including male subjects who have the ability to impregnate women and female subjects and their male partners)\n* Evidence of bleeding tendency or receiving thrombolytics or anticoagulants\n* According to the criteria of the term Common Adverse Events (NCI-CTCAE V5.0), the corresponding symptoms have been diagnosed;\n* Hepatitis B or hepatitis C virology tests at the time of screening meet any of the following: a) HBsAg positive and HBV-DNA titer ≥104 copy number \u002FmL or ≥2000IU\u002FmL (hepatitis B carriers should ask researchers for appropriate antiviral treatment); b) Active hepatitis C: HCV antibody positive and HCV-RNA higher than the lower detection limit of the assay;\n* Allergic to study drugs\n* The investigator believes that the subjects have other conditions that may affect their adherence to the protocol and evaluation of the study indicators, and the subjects are not suitable to participate in the study.",{"count":359,"type":21},116,[24],"This is a multicenter, double-blind, randomized, phase 2 trial to investigate the efficacy and safety of serlulimab combined with nab-paclitaxel plus SOX versus nab-paclitaxel plus SOX alone as neoadjuvant treatment for locally advanced GC or AEG.\n\nThe goal of this clinical trial is to learn if serlulimab combined with nab-paclitaxel plus SOX as neoadjuvant treatment for locally advanced AEG\u002FGC. It will also learn about the safety of serlulimab combined with nab-paclitaxel plus SOX. The main questions it aims to answer are:\n\nDoes serlulimab increase the pCR of participants with locally advanced AEG\u002FGC ? What medical problems do participants have when taking serlulimab? Researchers will compare to a placebo (a look-alike substance that contains no drug) to see if serlulimab combined with nab-paclitaxel plus SOX as neoadjuvant treatment for locally advanced AEG\u002FGC.\n\nParticipants will:\n\nEligible patients were randomly assigned to receive serlulimab (4.5 mg intravenously on day 1) combined with chemotherapy (nap-paclitaxel 260 mg\u002Fm2 intravenously on days 1, OXA 130mg\u002F \u002Fm2, intravenously on days 1, and S-1 40 to 60 mg orally twice daily depending on BSA on days 1 to 14) or chemotherapy alone every 3 weeks for 3 preoperative cycles followed by 3 postoperative cycles. All patients will be followed for survival.",[27,363],"Immune Checkpoint Inhibitors",[365,366,367],"Gastric cancer","Adenocarcinoma of Esophagogastric junction cancer","PD-1 antibody","2026-04-21",{"date":370,"type":32},"2026-04-23",{"date":372,"type":32},"2024-11-15",{"date":374,"type":21},"2026-09-30",{"name":376,"class":39},"Xijing Hospital",5,{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":22,"phases":387,"briefSummary":388,"conditions":389,"keywords":393,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":406},"100526215","phase-1-a-study-of-sgn-ceacam5c-in-adults-with-advanced-solid-tumors-100526215","NCT06131840","A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors","An Open-label Phase 1 Study to Investigate PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Tumor type:\n\n * Participants in Part A (dose escalation) and Part B (dose optimization) must have histologically- or cytologically-confirmed metastatic or unresectable solid tumor malignancy. Must have relapsed, refractory, or progressive disease, and should have no appropriate standard therapy available.\n\n * Participants in Part A must have one of the following tumor types: colorectal cancer (CRC); gastric carcinoma (GC) or gastroesophageal junction adenocarcinoma (GEJ); non-small cell lung cancer (NSCLC); or pancreatic ductal adenocarcinoma (PDAC).\n * The tumor types to be enrolled in Part B will be identified by the sponsor from among those specified in Part A.\n * Participants in Part C (dose expansion) must have one of the following histologically- or cytologically-confirmed metastatic or unresectable solid tumor malignancies.\n\n * CRC (adenocarcinoma of the colon or rectum) and must have received no more than 2 prior chemotherapy regimens for the treatment of advanced colorectal cancer and evidence of either progressive disease or intolerance to their last regimen.\n * PDAC with one or more metastatic lesions measurable by computed tomography\u002Fmagnetic resonance imaging according to RECIST v1.1 criteria; and must have received no more than 1 prior chemotherapy regimen for the treatment of advanced PDAC and evidence of either progressive disease or intolerance to that regimen.\n * GC or GEJ and must have received prior platinum and fluoropyrimidine-based chemotherapy.\n * NSCLC and must have received platinum-based therapy. If eligible and consistent with local standard of care must have received a PD-1\u002FPD-L1 inhibitor. In addition, participants with tumor genomic mutations\u002Falterations for which approved targeted therapies are available per local standard of care, must have received such therapies.\n * Small cell lung cancer (SCLC) and must have received platinum-based therapy for extensive-stage disease and no more than 3 prior lines of therapy. If eligible and consistent with local standard of care must have received a PD 1\u002FPD-L1 inhibitor.\n * CRC participants in Part D and Part E (bevacizumab combination therapy) must have histologically confirmed unresectable or metastatic adenocarcinoma of the colon or rectum. Received a maximum of 2 prior chemotherapy regimens for the treatment of advanced colorectal cancer and had demonstrated progressive disease or intolerance to their last regimen.\n * CRC participants in Part D and Part E (5FU\u002FLV + bevacizumab and 5FU\u002FLV + oxaliplatin + bevacizumab combination therapy) must have histologically confirmed unresectable or metastatic adenocarcinoma of the colon or rectum. Must not have received a prior TOPO1 inhibitor (such as irinotecan or nanoliposomal irinotecan) in any setting. 1L cohorts: No prior chemotherapy for advanced disease. 2L cohorts (applicable to 5FU\u002FLV + bevacizumab combination only): 1 prior chemotherapy regimen for the treatment of advanced disease, which must have included a fluoropyrimidine and oxaliplatin.\n\n \\> 2L PDAC participants in Part E (5FU\u002FLV combination therapy) must have histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma. One or more metastatic lesions measurable by computed tomography\u002Fmagnetic resonance imaging according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria.\n\n \\> 1L PDAC participants in Part E (5FU\u002FLV + oxaliplatin combination therapy) must have histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma that has not been previously treated in the metastatic setting. One or more metastatic lesions measurable by computed tomography\u002Fmagnetic resonance imaging according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria. No prior chemotherapy for PDAC with the following exception: Patients who received adjuvant\u002Fneoadjuvant chemotherapy and who had recurrence more than 12 months after completion of adjuvant\u002Fneoadjuvant chemotherapy are eligible.\n2. Participants enrolled in the following study parts should have a tumor site that is accessible for biopsy(ies) and agree to biopsy(ies) and\u002For submission of archival tissue:\n\n * Monotherapy dose optimization (Part B)\n * Monotherapy (Part C) and combination therapy (Part E) disease-specific expansion cohorts\n3. An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1\n4. Measurable disease per Response Evaluation in Solid Tumors (RECIST) v1.1 at baseline.\n\nExclusion Criteria:\n\n1. Previous exposure to CEACAM5-targeted therapy.\n2. Prior treatment with a TOPO1-targeting ADC (CPT payload), such as Enhertu (trastuzumab deruxtecan) or Trodelvy (sacituzumab govitecan).\n3. History of another malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy.\n4. Active cerebral\u002Fmeningeal disease related to the underlying malignancy. Participants with a history of cerebral\u002Fmeningeal disease related to the underlying malignancy are allowed if prior central nervous system disease has been treated and the participant is clinically stable (defined as not having received steroid treatment for symptoms related to cerebral\u002Fmeningeal disease for at least 2 weeks prior to enrollment and with no ongoing related AEs).\n\n \\> Criteria related to bevacizumab administration (participants in Parts D and E)\n5. History of allergic reactions or hypersensitivity to bevacizumab or any of its excipients.\n6. History of hypersensitivity to Chinese Hamster Ovary cell products or other recombinant human or humanized antibodies.\n7. Serious non-healing wound, non-healing ulcer, or non-healing bone fracture.\n8. Deep venous thromboembolic event within 4 weeks prior to enrollment\n9. Known coagulopathy that increases risk of bleeding, bleeding diatheses.\n10. History of any life-threatening VEGF-related adverse event",{"count":386,"type":21},914,[115],"This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat.\n\nParticipants in this study must have cancer that has come back or did not get better with treatment. Participants must have a solid tumor cancer that can't be treated with standard of care drugs.\n\nThis clinical trial uses an experimental drug called PF-08046050. PF-08046050 is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells.\n\nThis study will test the safety of PF-08046050 in participants with solid tumors that are hard to treat or have spread throughout the body.\n\nThis study has 5 different study parts. Part A and Part B of the study will find out how much PF-08046050 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046050 is safe and if it works to treat certain solid tumor cancers. Part D and E of the study, together with information from Parts A and B, will find out how much PF-08046050 should be given in combination with other anti-cancer agents. Part E will use the information from Parts A, B, and D to see if PF-08046050 is safe in combination with other anti-cancer agents and if it works to treat a certain solid tumor.",[119,390,27,391,293,392],"Carcinoma, Non-Small-Cell Lung","Pancreatic Ductal Adenocarcinoma","Small Cell Lung Carcinoma",[394,299,395,396,304,397,313],"CRC","PDAC","GC","SCLC","2026-04-17",{"date":400,"type":32},"2026-04-20",{"date":402,"type":32},"2023-11-20",{"date":404,"type":21},"2030-09-12",{"name":321,"class":134},44,{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":413,"eligibilityCriteria":414,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":415,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":417,"conditions":418,"keywords":420,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":434},"100631763","spanish-validation-of-koquss-40-questionnaire-assessing-qol-of-gastric-cancer-patients-after-gastrectomy-spquss-41-100631763","NCT07504913","Spanish Validation of KOQUSS-40 Questionnaire: Assessing QoL of Gastric Cancer Patients After Gastrectomy: SPQUSS-41","SPQUSS-41: Validación Del Cuestionario de Calidad de Vida KOQUSS-40 Para Los Pacientes Con gastrectomía Por cáncer gástrico [SPQUSS-41]","SPQUSS-41","Inclusion Criteria:\n\n* Patients operated on for gastric cancer with curative intent from 1 month postoperatively up to the last 5 years\n* Adult patients over 18 years old\n* No recurrence of the disease\n* Patients who have given their informed consent to participate in the Spanish EURECCA Registry of Esophagogastric Cancer and have signed the specific consent for the SPQUSS-4 study\n\nExclusion Criteria:\n\n* First 30 days after surgery and\u002For patients with postoperative complications requiring more than 30 days of hospitalization.\n* Patients who do not give their consent to participate in the study will be excluded.\n* Patients with a history of other neoplasms.\n* Patients with disseminated gastric cancer or candidates for palliative surgery, as well as those patients who do not give their consent to participate.",{"count":416,"type":21},505,"The main objective of this study is the translation, linguistic adaptation into Spanish, and validation of the Korean quality of life questionnaire KOQUSS-40. This tool will allow us to objectively measure the quality of life of patients in clinical trials.",[27,419],"Validation Study",[421,422,423,424],"Stomach neoplasms","Validation study","Surveys and questionnaires","Quality of life","2026-03-26",{"date":427,"type":32},"2026-04-01",{"date":429,"type":32},"2025-05-03",{"date":431,"type":21},"2026-12-01",{"name":433,"class":39},"Parc de Salut Mar",6,{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":441,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":445,"conditions":446,"keywords":449,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":40},"100435402","prevalence-of-helicobacter-pylori-infection-and-gastric-cancer-in-the-west-indies-100435402","NCT04949737","Prevalence of Helicobacter Pylori Infection and Gastric Cancer in the West Indies","Prevalence of Helicobacter Pylori Infection and Gastric Cancer in the West Indies: Helico-MQ Interventional Study","Hélico-MQ","Inclusion Criteria:\n\n1. Patient over 18 years of age, residing for at least 6 months in Martinique, with a primary diagnosis of gastric cancer\n2. Patient having read the information note and having signed the consent to participate in the study\n3. Patient with social security coverage\n\nExclusion Criteria:\n\n1. Refusal to participate\n2. Patient who could not answer the questionnaires\n3. Patient not affiliated to a social security system\n4. Patient not fluent in French\n5. Patient under legal protection (legal protection, guardianship, curators, etc.)",{"count":444,"type":21},112,"Estimating the prevalence of Helicobacter Pylori infection in newly diagnosed stomach cancers in the West-Indies will help to understand the epidemiology of this cancer, which is over-incident in the West Indies compared to France. In addition, the constitution of a biobank (tumor tissues, healthy tissues and serum) will allow to set up in a second time etiological studies to identify other risk factors in particular in connection with the exposure to environmental pollutants to adapt the prevention measures.",[27,447,448],"Gastric Neoplasms","Helicobacter Pylori",[448,365,450,451],"Prevalence","French West-Indies",{"date":453,"type":32},"2026-03-31",{"date":455,"type":32},"2025-10-09",{"date":457,"type":21},"2028-12",{"name":459,"class":39},"University Hospital Center of Martinique",{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":466,"eligibilityCriteria":467,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":468,"enrollmentInfo":469,"targetDuration":4,"studyType":22,"phases":471,"briefSummary":472,"conditions":473,"keywords":475,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":40},"100630045","proximal-versus-total-gastrectomy-for-locally-advanced-siewert-type-ii-iii-gastroesophageal-junction-cancer-100630045","NCT07482566","Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer","A Multicenter Prospective Randomized Double-Blind Clinical Trial Comparing Proximal Gastrectomy and Total Gastrectomy in Patients With Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer","SIEWERT-RCT","Inclusion Criteria:\n\n* Age between 18 and 90 years\n* Histologically confirmed locally advanced Siewert type II-III gastroesophageal junction cancer\n* Considered operable after multidisciplinary tumor board evaluation\n* Candidate for curative surgical resection with D2 lymphadenectomy\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Early-stage gastroesophageal junction cancer\n* Gastric cancers located in the antrum or corpus\n* Severe anesthetic risk (American Society of Anesthesiologists \\[ASA\\] class IV or higher)\n* Pregnancy\n* Patients unwilling or unable to provide informed consent","90 Years",{"count":470,"type":21},120,[85],"This multicenter prospective randomized clinical trial aims to compare the safety and oncological effectiveness of proximal gastrectomy and total gastrectomy in patients with locally advanced Siewert type II-III gastroesophageal junction cancer. Eligible patients will be randomly assigned to undergo either proximal gastrectomy or total gastrectomy using open, laparoscopic, or robotic surgical approaches according to clinical suitability. The primary outcome of the study is 3-year disease-free survival. Secondary outcomes include postoperative mortality, postoperative complications, and the number of metastatic lymph nodes retrieved. Patients will be followed for up to five years after surgery to evaluate long-term oncological outcomes.",[474,27,123],"Gastroesophageal Junction Cancer",[476,477,478,479,480],"Siewert Type II","Siewert Type III","Proximal Gastrectomy","Total Gastrectomy","Gastric Cancer Surgery","2026-03-18",{"date":483,"type":32},"2026-03-20",{"date":485,"type":32},"2026-02-01",{"date":487,"type":21},"2033-02-01",{"name":489,"class":490},"Nurettin Şahin","OTHER_GOV",{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":17,"minAge":498,"maxAge":4,"enrollmentInfo":499,"targetDuration":4,"studyType":22,"phases":501,"briefSummary":502,"conditions":503,"keywords":507,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":524},"100605358","argon-plasma-coagulation-versus-endoscopic-mucosal-resection-for-gastric-adenoma-cler-ga-100605358","NCT07161479","Argon Plasma Coagulation Versus Endoscopic Mucosal Resection for Gastric Adenoma (CLER-GA)","A Multicenter, Randomized, Single-Blinded Trial Comparing Argon Plasma Coagulation and Endoscopic Mucosal Resection for Gastric Adenoma With Low-Grade Dysplasia","Inclusion Criteria:\n\n* Adults aged 20 years or older\n* Diagnosed with gastric adenoma with low-grade dysplasia measuring ≤ 1 cm on endoscopy\n* Scheduled to undergo endoscopic treatment\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Previous treatment for gastric adenoma or gastric cancer\n* History of gastrectomy\n* Diagnosis of gastric cancer or high-grade dysplasia at the time of enrollment\n* Presence of multiple gastric adenomas\n* Pregnant, breastfeeding, or possibility of pregnancy\n* Uncontrolled chronic illnesses that may interfere with trial participation (e.g., uncontrolled hypertension, uncontrolled diabetes, chronic kidney disease, ascites, heart failure, psychiatric disorders)","20 Years",{"count":500,"type":21},160,[85],"Gastric adenomas with low-grade dysplasia (LGD) are considered precancerous lesions of the stomach. While these lesions carry a lower risk of progressing to gastric cancer compared with high-grade dysplasia, there is still uncertainty about the best way to manage them. International medical guidelines differ in their recommendations, and for very small lesions (1 cm or smaller), some guidelines provide no clear direction. This creates uncertainty for both patients and physicians about whether to treat these lesions or simply observe them over time.\n\nTwo endoscopic treatment methods are widely used in clinical practice: endoscopic mucosal resection (EMR) and argon plasma coagulation (APC). EMR involves lifting and cutting out the lesion. Its major advantage is that it removes the lesion completely and allows for detailed pathological examination. However, EMR can be technically more demanding, takes more time, and may carry higher risks of complications such as bleeding or perforation. It also usually involves higher medical costs.\n\nIn contrast, APC is a technique that uses ionized argon gas and electrical current to coagulate tissue without direct contact. APC is simpler to perform, takes less time, and is generally less invasive. Patients undergoing APC may have shorter hospital stays, lower costs, and fewer complications. However, APC does not provide a specimen for pathology, so complete removal of the lesion cannot be confirmed. This means there is a possibility of local recurrence.\n\nSeveral retrospective studies have examined APC for gastric LGD, and results have suggested it may be effective for small lesions. However, recurrence rates reported in previous studies have varied widely, from less than 2% to more than 20%. Importantly, no large randomized controlled trial has directly compared APC with EMR for small gastric LGD lesions. This study seeks to fill that gap.\n\nThe goal of this clinical trial is to compare the effectiveness and safety of APC and EMR for treating gastric adenomas that are 1 cm or smaller with low-grade dysplasia. Specifically, the study aims to determine whether APC is \"non-inferior\" to EMR in preventing local recurrence of these lesions. In other words, researchers want to know if APC works just as well as EMR in controlling the disease, while also offering potential advantages such as fewer complications, shorter procedure time, and lower costs.\n\nParticipants in this study will:\n\nBe adults (age 20 or older) diagnosed with a gastric adenoma 1 cm or smaller with low-grade dysplasia.\n\nBe randomly assigned (by chance, like flipping a coin) to receive either APC or EMR.\n\nReceive standard medical care after the procedure, including medications to help the stomach heal.\n\nReturn for follow-up endoscopy at 3 months and 12 months after the procedure. During these visits, the treated area will be checked carefully, and biopsies may be taken to determine whether the lesion has recurred.\n\nProvide information about any complications, the duration of the procedure, and their recovery experience.\n\nThe main question is whether APC can prevent recurrence of gastric adenomas as effectively as EMR. Secondary questions include how the two treatments differ in terms of complications (such as bleeding or perforation) and procedure time.\n\nBoth APC and EMR are already established and commonly used treatments for gastric lesions. By directly comparing these two methods in a randomized controlled trial, this study will provide important evidence to guide future recommendations for patients with small gastric adenomas. The findings may help physicians and patients choose the best treatment option, balancing safety, effectiveness, and convenience.",[504,27,505,506],"Gastric Adenoma","Precancerous Conditions","Dysplasia Stomach",[508,509,510,511,512,513,514,515,421],"Gastric adenoma","Low-grade dysplasia","Precancerous gastric lesion","Argon plasma coagulation (APC)","Endoscopic mucosal resection (EMR)","Endoscopic therapy","Local recurrence","Randomized controlled trial","2026-02-04",{"date":518,"type":32},"2026-02-06",{"date":520,"type":32},"2026-01-20",{"date":522,"type":21},"2026-10",{"name":252,"class":39},3,{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":206,"enrollmentInfo":532,"targetDuration":4,"studyType":22,"phases":534,"briefSummary":535,"conditions":536,"keywords":537,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":549,"locationsCount":40},"100616713","phase-2-adebrelimab-combined-with-famitinib-and-irinotecan-in-advanced-gastric-cancer-after-failure-of-first-line-therapy-100616713","NCT07309185","Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy","Adebrelimab Combined With Famitinib Malate and Irinotecan Versus Irinotecan in Patients With Advanced Gastric Cancer After Failure of First-Line Therapy: A Randomized, Controlled, Exploratory Clinical Study","Inclusion Criteria:\n\n* 1\\. Patients with advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma diagnosed by histology or cytology;\n* 2\\. Patients who have previously failed first-line treatment including systemic chemotherapy and immune checkpoint inhibitors, and have maintained first-line use of immune checkpoint inhibitors for at least 3 months;\n* 3\\. According to the evaluation criteria for solid tumor efficacy 1.1 (RECIST v1.1), there should be at least one measurable lesion that has not received local treatment such as radiotherapy (lesions located within the previously irradiated area can also be selected as target lesions if progression is confirmed);\n* 4\\. ECOG score: 0-1 point;\n* 5\\. Expected survival period ≥ 12 weeks;\n* 6\\. The main organ functions well and the laboratory test data meets the following standards: (1) Blood routine: absolute neutrophil count ≥ 1.5 × 109\u002FL (or greater than the lower limit of normal laboratory values in the research center), platelet count ≥ 100 × 109\u002FL, hemoglobin ≥ 90g\u002FL; (2) Liver function: serum total bilirubin ≤ 1.5 times the upper limit of the standard value (ULN), AST and ALT ≤ 2.5 times ULN. If the patient has liver metastasis, this standard is ≤ 5 times ULN; (3) Renal function: CrCl ≥ 60 ml\u002Fmin\u002F1.73 m2 (calculated according to the Cockcroft Gault formula);\n* 7\\. Female subjects with fertility, as well as male subjects with partners who are fertility women, are required to use a medically approved contraceptive measure (such as intrauterine device, contraceptive pill, or condom) during the study treatment period, at least 6 months after the last use of Adebrelimab, and at least 6 months after the last use of chemotherapy;\n* 8\\. Voluntarily join this study, sign the informed consent form, have good compliance, and cooperate with follow-up.\n\nExclusion Criteria:\n\n* 1\\. History of gastrointestinal perforation and\u002For fistula within 6 months prior to the first use of medication;\n* 2\\. There is uncontrollable pleural effusion, pericardial effusion, or peritoneal effusion that requires repeated drainage;\n* 3\\. History of allergies to any component of Adebrelimab in the past;\n* 4\\. Have received any of the following treatments:\n\n 1. Received any other investigational drug within 4 weeks prior to the first use of the investigational drug or had a half-life of no more than 5 from the last investigational drug;\n 2. Simultaneously enrolled in another clinical study, unless it is an observational (non interventional) clinical study or an interventional clinical study follow-up;\n 3. Received anti-tumor therapy (including radiotherapy, chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, or tumor embolization) within 2 weeks prior to the first use of the investigational drug;\n 4. Subjects who need to receive corticosteroids (equivalent to\\>10mg prednisone per day) within 2 weeks prior to the first use of the study drug. Allow the use of hormones for routine chemotherapy pretreatment without the need for dose adjustment. Other special circumstances require communication with the researcher. In the absence of active autoimmune diseases, inhalation or local use of steroids and corticosteroids with a dosage greater than 10mg\u002Fday of prednisone efficacy dose are allowed as substitutes for adrenal cortex hormones;\n 5. Individuals who have received anti-tumor vaccines or have received live vaccines within 4 weeks prior to the first administration of the study drug;\n 6. Having undergone major surgery or suffered severe trauma within 4 weeks prior to the first use of the investigational drug;\n 7. Patients who have received previous treatment with paclitaxel drugs;\n* 5\\. The toxicity of previous anti-tumor treatments has not recovered to ≤ CTCAE 5.0 Grade 1 (excluding hair loss) or the level specified in the inclusion\u002Fexclusion criteria;\n* 6\\. Patients with active central nervous system metastases;\n* 7\\. Active autoimmune diseases, history of autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to the above diseases or syndromes); Excluding childhood asthma\u002Fallergies with vitiligo or those who have already recovered, patients who do not require any intervention in adulthood; Autoimmune mediated hypothyroidism treated with stable doses of thyroid replacement hormone; Type I diabetes with a stable dose of insulin;\n* 8\\. Have a history of immune deficiency, including HIV test positive, or have other acquired or congenital immune deficiency diseases, or have a history of organ transplantation and allogeneic bone marrow transplantation, or active hepatitis (hepatitis B reference: HBV DNA test value exceeds 500 IU\u002Fml or 2500 copies\u002FmL);\n* 9\\. The subject has uncontrolled cardiovascular clinical symptoms or diseases, including but not limited to: (1) NYHA class II or above heart failure; (2) Unstable angina pectoris; (3) Have experienced myocardial infarction within one year; (4) Clinically significant supraventricular or ventricular arrhythmias that have not been clinically intervened or are still poorly controlled after clinical intervention;\n* 10\\. Within 4 weeks prior to the first use of the investigational drug, there has been a severe infection (CTCAE 5.0\\>grade 2), such as severe pneumonia requiring hospitalization, bacteremia, infection complications, etc; Baseline chest imaging examination suggests the presence of active pulmonary inflammation, symptoms and signs of infection within 2 weeks prior to the first use of the study drug, or the need for oral or intravenous antibiotic treatment, except for prophylactic use of antibiotics;\n* 11\\. History of interstitial lung disease (excluding history of radiation pneumonia and non infectious pneumonia that have not been treated with steroids);\n* 12\\. Patients with active pulmonary tuberculosis infection found through medical history or CT examination, or patients with a history of active pulmonary tuberculosis infection within the past year before enrollment, or patients with a history of active pulmonary tuberculosis infection more than one year ago but without formal treatment;\n* 13\\. Diagnosed with any other malignant tumor within 5 years prior to the first use of the investigational drug, except for malignant tumors with low-risk metastasis and mortality risk (5-year survival rate\\>90%), such as basal cell or squamous cell carcinoma or cervical carcinoma in situ that have been adequately treated;\n* 14\\. Pregnant or lactating women;\n* 15\\. According to the researcher's assessment, there may be other factors that could force the subject to terminate the study midway, such as having other serious illnesses (including mental illnesses) that require concurrent treatment, severe abnormal laboratory test values, family or social factors that may affect the subject's safety or the collection of trial data.",{"count":533,"type":21},66,[24],"This study employs a randomized, controlled, exploratory clinical trial design, with a planned enrollment of 66 patients who have previously failed systemic chemotherapy for recurrent\u002Fmetastatic gastric cancer,",[27],[538,539,540,541],"Immune checkpoint inhibitors","Adebrelimab Injection","Famitinib","Second line treatment for advanced","2025-12-29",{"date":544,"type":32},"2025-12-30",{"date":546,"type":32},"2024-07-24",{"date":548,"type":21},"2028-07-31",{"name":550,"class":39},"Shandong Tumor Hospital",{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":556,"acronym":4,"eligibilityCriteria":557,"healthyVolunteers":12,"sex":17,"minAge":558,"maxAge":206,"enrollmentInfo":559,"targetDuration":4,"studyType":22,"phases":560,"briefSummary":561,"conditions":562,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":4},"100612967","the-efficacy-and-safety-of-laparoscopic-proximal-gastrectomy-with-lpg-tbrosf-versus-ltg-for-localized-proximal-gastric-cancer-100612967","NCT07260461","The Efficacy and Safety of Laparoscopic Proximal Gastrectomy With LPG-tbROSF Versus LTG for Localized Proximal Gastric Cancer.","A Multicenter, Prospective, Randomized Controlled Clinical Trial on the Efficacy and Safety of Laparoscopic Proximal Gastrectomy With Tubular Stomach-Based Right-Opening Single Flap Valvuloplasty (LPG-tbROSF) Versus Laparoscopic Total Gastrectomy for Localized Proximal Gastric Cancer.","Inclusion Criteria:\n\n1. Aged from 18 to 75 years old;\n2. Histologically confirmed proximal gastric adenocarcinoma, CT1-2N0M0 stage;\n3. The tumor was located in the proximal third of the stomach.\n4. ECOG score of 0 or 1;\n5. D1+ or D2 dissection according to guidelines (depending on tumor location and intraoperative evaluation).\n6. ASA grade I to III;\n7. The preoperative nutritional status of the patients was good without severe malnutrition.\n8. Voluntarily sign informed consent.\n\nExclusion Criteria:\n\n1. Concurrent with other active malignant tumors, or a history of other malignant tumors within 5 years (excluding basal cell carcinoma of the skin and carcinoma in situ of the cervix);\n2. Severe cardiovascular diseases: such as NYHA class Ⅲ and above cardiac dysfunction, recent myocardial infarction (within 6 months), refractory hypertension or arrhythmia;\n3. Severe respiratory diseases: severe impairment of lung function (FEV1%\\\u003C50%) or chronic respiratory failure;\n4. Severe liver and kidney dysfunction: ALT\u002FAST \\> 3 times the upper limit of normal, or eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²;\n5. patients complicated with other major chronic diseases, such as active tuberculosis, rheumatoid, systemic lupus erythematosus and other autoimmune diseases that affect surgical tolerance;\n6. Tumor imaging suggested the presence of distant metastasis (M1) or regional lymph node involvement, and the tumor was unresectable.\n7. Complicated with other upper gastrointestinal diseases, such as active gastric ulcer, pyloric obstruction, persistent bleeding, which seriously affect the operation;\n8. Previous major gastric or upper abdominal surgery (such as subtotal gastrectomy, esophagogastric anastomosis, etc.) affecting the reconstruction method;\n9. Received preoperative neoadjuvant chemoradiotherapy or targeted therapy (unless specifically permitted by the study design);\n10. Pregnant or lactating women;\n11. Patients with mental disorders, cognitive impairment, poor compliance, inability to understand the study content, or inability to cooperate with the follow-up;\n12. Severe malnutrition before surgery: BMI \\\u003C 16 kg\u002Fm² or albumin \\\u003C 25 g\u002FL;\n13. Other individual conditions deemed unsuitable for enrollment by the investigator (e.g., poor willingness to cooperate, high risk of loss to follow-up, etc.).","15 Years",{"count":470,"type":21},[85],"This clinical trial is evaluating a new, function-preserving surgical technique for patients with early-stage cancer in the upper part of the stomach.\n\nThe current standard treatment is a Laparoscopic Total Gastrectomy (LTG), which involves the complete removal of the stomach. This study compares the standard LTG with an innovative procedure called Laparoscopic Proximal Gastrectomy combined with a novel anti-reflux reconstruction (LPG-tbROSF). This new technique removes only the cancerous upper portion of the stomach, aiming to preserve digestive functions and reduce post-surgery complications like acid reflux.\n\nThe main goal is to see if patients who receive the new, stomach-preserving surgery experience less body weight loss one year after the procedure compared to those who undergo the standard total gastrectomy. The research will also compare the two surgeries in terms of post-operative quality of life, nutritional status, acid reflux symptoms, safety, and long-term cancer outcomes.\n\nThe study is a multi-center, prospective, randomized controlled trial that plans to enroll 120 patients with localized cancer in the upper stomach.",[27,563,474],"Adenocarcinoma - Gastroesophageal Junction (GEJ)","2025-12-02",{"date":566,"type":32},"2025-12-03",{"date":568,"type":21},"2026-01-01",{"date":570,"type":21},"2028-09-01",{"name":275,"class":39},{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":576,"acronym":577,"eligibilityCriteria":578,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":206,"enrollmentInfo":579,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":581,"conditions":582,"keywords":586,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":594,"locationsCount":40},"100424601","comparation-of-endoscopic-biopsy-and-postoperative-specimen-for-the-molecular-diagnosis-of-gastric-cancer-100424601","NCT04809025","Comparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric Cancer","EBPS","Inclusion Criteria:\n\n1. Lower age limit of research subjects 18 years old and upper age limit of 75 years old.\n2. Histologically proven primary gastric adenocarcinoma (Diagnostic biopsies must be collected within 12 months prior to enrollment).\n3. Written informed consent from the patient.\n4. Patients planned for radical R0 gastrectomy.\n\nExclusion Criteria:\n\n1. Female in pregnancy or lactation.\n2. Patients with gastric cancer who can not undergo tumor resection\n3. Suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, complicated by poorly controlled hypertension, diabetes, mental disorders or diseases.\n4. Patients with poor compliance or considered to be poor compliance.\n5. Patients received any anticancer drugs, biotherapy, radiotherapy or immunotherapy within 4 weeks before or after enrollment.\n6. Patients after organ transplantation, long-term need to take immunosuppressants, autoimmune diseases.",{"count":580,"type":21},510,"This study aims to test the hypothesis that the diagnosis for histological type, histological grade, LAUREN type, HER-2 expression, MSI\u002FdMMR status, and EBV status in gastric cancer is at least as reliable when performed on endoscopic biopsy specimens as on surgical resection specimens.",[27,583,584,585],"Endoscopy","Biopsy","Pathology",[27,583,584,585],"2025-09-24",{"date":589,"type":32},"2025-09-29",{"date":591,"type":32},"2021-05-24",{"date":593,"type":21},"2026-09-01",{"name":595,"class":39},"Fudan University",{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":602,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":206,"enrollmentInfo":604,"targetDuration":4,"studyType":22,"phases":606,"briefSummary":607,"conditions":608,"keywords":609,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":612,"lastUpdatePostDateStruct":613,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":40},"100417059","multicenter-study-on-laparoscopic-total-gastrectomy-for-advanced-gastric-cancer-100417059","NCT04710758","Multicenter Study on Laparoscopic Total Gastrectomy for Advanced Gastric Cancer","Prospective Randomized Controlled Multicenter Clinical Trial For Comparison Of Long-term Outcomes Between Laparoscopic And Open Total Gastrectomy In Patients With Locally Advanced Gastric Cancer","CLASS-07","Inclusion Criteria:\n\n1. Aged 18-75 years\n2. Tumor located in the middle or upper third of the stomach, and curative resection is expected to be achievable by total gastrectomy with D2 lymphadenectomy (also apply to multiple primary cancers);\n3. Primary lesion is pathologically diagnosed as gastric adenocarcinoma, such as papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, poorly cohesive carcinoma (including signet ring cell carcinoma and other variants), and mixed adenocarcinoma;\n4. Clinical stage T2-4aN0-3M0 (According to AJCC-8th TNM staging system);\n5. Expected survival \\> 6 months\n6. No invasion to Z-line;\n7. BMI (Body Mass Index) \\\u003C 30 kg\u002Fm2\n8. No history of upper abdominal surgery (except for laparoscopic cholecystectomy);\n9. No prior treatment of chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc\n10. Preoperative performance status (ECOG，Eastern Cooperative Oncology Group) of 0 or 1\n11. Preoperative ASA (American Society of Anesthesiologists) scoring: I-III\n12. Sufficient organ functions\n13. Written informed consent\n\nExclusion Criteria:\n\n1. Preoperative examinations indicate regional fusion of enlarged lymph nodes (max diameter ≥ 3.0cm) or enlargment of spleen hilus lymph nodes\n2. Women during pregnancy or breast-feeding\n3. Synchronous or metachronous (within 5 years) malignancies\n4. Body temperature ≥ 38℃ before surgery or infectious disease with a systemic therapy indicated\n5. Severe mental disease\n6. Severe respiratory disease, FEV1 \\\u003C 50% of predicted\n7. Severe hepatic and renal dysfunction\n8. Unstable angina pectoris or history of myocardial infarction within 6 months\n9. History of cerebral infarction or cerebral hemorrhage within 6 months\n10. Continuous systemic steroid therapy within 1 month (except for topical use)\n11. Gastric cancer complications (bleeding, perforation, obstruction) that requiring emergency surgery\n12. Patients are participating or have participated in another clinical trial (within 6 months)",{"count":605,"type":21},1018,[85],"CLASS-07 trial is a prospective, multicenter, randomized controlled trial for comparison of long-term outcomes between laparoscopic total gastrectomy (LTG) and open total gastrectomy (OTG) in patients with locally advanced gastric cancer (clinical stage T2-4aN0-3M0). The primary purpose of this study is to evaluate the overall survival and determine the efficacy of LTG compared with OTG for locally advanced gastric cancer. The second purpose is to evaluate the 3-year overall survival rate, 3-year disease free survival rate, morbidity and mortality rates, 3-year recurrence pattern and postoperative recovery course of the patients enrolled in this study.",[27],[27,610,611],"Laparoscopic total gastrectomy","Open total gastrectomy","2025-09-16",{"date":614,"type":32},"2025-09-22",{"date":616,"type":32},"2021-01-20",{"date":618,"type":21},"2028-12-31",{"name":620,"class":39},"Shanghai Zhongshan Hospital",{"id":622,"slug":623,"hasResults":12,"nctId":624,"briefTitle":625,"officialTitle":626,"acronym":4,"eligibilityCriteria":627,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":260,"enrollmentInfo":628,"targetDuration":4,"studyType":22,"phases":629,"briefSummary":630,"conditions":631,"keywords":633,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":638,"lastUpdatePostDateStruct":639,"startDateStruct":641,"completionDateStruct":643,"leadSponsor":645,"locationsCount":40},"100607038","family-supervised-prehabilitation-to-reduce-postoperative-complications-after-neoadjuvant-chemotherapy-in-gastric-cancer-100607038","NCT07183358","Family-Supervised Prehabilitation to Reduce Postoperative Complications After Neoadjuvant Chemotherapy in Gastric Cancer","Effect of Family-Supervised Multimodal Prehabilitation Throughout Preoperative Neoadjuvant Chemotherapy on Clinical Outcomes in Gastric Cancer Patients: A Single-Center Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18-80 years\n* Histologically proven gastric adenocarcinoma by gastroscopy\n* Clinical stage T2-4a, N any, M0 planned for neoadjuvant chemotherapy plus radical gastrectomy\n* ECOG performance status 0-1; ASA class I-III\n* Able to understand the study and provide signed informed consent\n\nExclusion Criteria:\n\n* Previous or concurrent malignancies\n* Emergent conditions (bleeding, perforation, obstruction) requiring immediate surgery\n* Pregnant or lactating women\n* Severe psychiatric disorders\n* Prior major abdominal surgery (except laparoscopic cholecystectomy)\n* Unstable angina, myocardial infarction, or cerebrovascular event within 6 months\n* Continuous use of NSAIDs, corticosteroids, or probiotics within 1 month\n* Simultaneous surgery for other diseases\n* FEV1 \\\u003C 50 % predicted\n* Any condition that, in the investigator's opinion, contraindicates participation",{"count":262,"type":21},[85],"This study evaluates whether a family-supervised exercise-nutrition-psychology program can reduce complications after stomach-cancer surgery. Eligible patients are adults who will receive chemotherapy before surgery. Participants are randomly assigned to either the multimodal prehabilitation program plus usual care or usual care alone. The main outcome is the rate of serious complications within 30 days after surgery. Potential benefits include fewer complications and faster recovery; risks are minimal and mainly related to mild exercise fatigue.",[27,632],"Neoadjuvant Therapy",[634,635,636,637,215],"prehabilitation","postoperative complications","multimodal","family-supervised","2025-09-13",{"date":640,"type":32},"2025-09-19",{"date":642,"type":21},"2025-09-20",{"date":644,"type":21},"2026-06-20",{"name":646,"class":39},"The Affiliated Hospital of Qingdao University",{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":651,"acronym":4,"eligibilityCriteria":652,"healthyVolunteers":653,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":654,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":656,"conditions":657,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":659,"lastUpdatePostDateStruct":660,"startDateStruct":662,"completionDateStruct":664,"leadSponsor":666,"locationsCount":40},"100595679","diagnosis-of-multiple-cancer-and-monitoring-of-minimal-residual-tumors-after-treatment-using-blood-and-high-sensitivity-genetic-analysis-techniques-100595679","NCT07035587","Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques","Inclusion Criteria:\n\n* Age ≥ 19 years\n* Voluntarily agreed to participate and provided informed consent\n* Able to donate blood without health risks\n* Underwent or is scheduled to undergo surgery or chemotherapy for therapeutic purposes for cancer (for cancer group)\n* Diagnosed with one of the following cancers: ovarian, lung, pancreatic, colorectal, esophageal, breast, bladder, kidney, or gastric cancer\n* Control group: asymptomatic individuals with gallstones or benign polyps, or subjects undergoing routine health screenings\n* Control group must have confirmed benign findings through imaging (ultrasound, CT, LDCT, colonoscopy)\n\nExclusion Criteria:\n\n* Age \\\u003C 19 years\n* Patients with mental retardation or severe psychiatric disorders affecting informed consent\n* History of HIV, HTLV, or syphilis infection\n* History of other malignancy within 5 years (for cancer group)\n* No somatic mutation detected in tumor or pre-treatment cfDNA (for cancer group)\n* Control group with any past or current cancer diagnosis\n* Control group with high-grade adenoma, symptomatic gallstones\u002Fpolyps, or recent (\\\u003C6 months) abdominal surgery\n* Pregnant or breastfeeding women\n* Any other reason deemed inappropriate by the investigator",true,{"count":655,"type":21},1200,"This is a combined prospective and retrospective observational study aiming to validate a highly sensitive and specific blood-based method for the early diagnosis and post-treatment monitoring of multiple cancers. The study leverages a newly developed sequencing method to improve the detection of circulating tumor DNA (ctDNA) in blood, focusing on enhancing sensitivity and specificity in clinical applications.\n\nThe study targets patients with ovarian, lung, pancreatic, colorectal, esophageal, breast, kidney, bladder, and gastric cancer, as well as healthy controls with asymptomatic gallstones, benign polyps, or individuals undergoing routine medical screening. Blood samples will be analyzed for cell-free DNA (cfDNA), RNA, and protein profiles. A key objective is to determine how much the newly developed method increases the sensitivity and specificity of ctDNA detection, especially in early-stage cancers and minimal residual disease (MRD) after treatment.\n\nThe method evaluates the variant allele frequency (VAF) of ctDNA to detect residual disease and track tumor dynamics. Serial blood sampling will be conducted before and after surgery or chemotherapy and during follow-up outpatient visits in cancer patients, while one-time sampling will be done for controls. Additionally, tissue biopsies collected during surgery will be used to analyze concordance between tumor-specific mutations and those found in ctDNA.\n\nPrimary outcome measures include quantitative differences in ctDNA or RNA levels between cancer and control groups. Secondary outcomes assess the clinical correlation between changes in ctDNA VAF and patient outcomes such as recurrence and survival. Statistical tools including ROC curve analysis, Cox regression, and log-rank tests will be used to quantify performance.\n\nThis study seeks to establish a clinically robust, non-invasive diagnostic tool that enables earlier detection and more precise treatment decisions, while potentially reducing physical, psychological, and socioeconomic burdens related to cancer care.",[63,56,119,123,64,27,658,148],"Neoplasm Micrometastasis","2025-06-15",{"date":661,"type":32},"2025-06-25",{"date":663,"type":32},"2024-08-21",{"date":665,"type":21},"2029-07-28",{"name":667,"class":39},"Yonsei University",{"id":669,"slug":670,"hasResults":12,"nctId":671,"briefTitle":672,"officialTitle":673,"acronym":4,"eligibilityCriteria":674,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":675,"targetDuration":4,"studyType":22,"phases":677,"briefSummary":678,"conditions":679,"keywords":686,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":692,"lastUpdatePostDateStruct":693,"startDateStruct":695,"completionDateStruct":697,"leadSponsor":699,"locationsCount":377},"100511807","phase-1-htl0039732-in-participants-with-advanced-solid-tumours-100511807","NCT05944237","HTL0039732 in Participants With Advanced Solid Tumours","A Cancer Research UK Phase I\u002FIIa Trial of HTL0039732, Given Orally as Monotherapy and in Combination With Immunotherapy or Other Approved Therapies in Participants With Advanced Solid Tumours","Inclusion Criteria:\n\n1. Written (signed and dated) informed consent and capable of co-operating with investigational medicinal product administration and follow-up.\n2. Phase 1, dose escalation phase\n\n Part A (HTL0039732 monotherapy):\n * Histologically or cytologically proven advanced solid tumour, refractory to conventional treatment, or for which no further conventional therapy is considered appropriate by the Investigator or is declined by the potential participant.\n * At least 1 measurable lesion according to RECIST v1.1, which (in the Investigator's opinion) has had objective radiological progression on or after the last therapy, or at least one assessable lesion e.g. pleural or peritoneal thickening that does not fulfil RECIST v1.1 criteria for measurable disease.\n\n a. Consent for fresh tumour biopsy sample(s) at time of PD, if the participant has accessible disease and is eligible to receive atezolizumab. Optional at time of disease progression.\n * Consent to access and analysis of any available archival tissue or a fresh tumour sample at baseline, if archival tissue is unavailable.\n * Consent for fresh tumour biopsy sample(s) at time of PD, if the participant has accessible disease and is eligible to receive atezolizumab. Optional at time of disease progression.\n\n Phase 1 Part B:\n\n \\- Histologically proven advanced solid tumour where PGE2\u002FEP4 signalling is believed to be more prevalent or significant (such as microsatellite stable colorectal cancer (MSS CRC), gastro-esophageal cancer, head and neck squamous cell carcinoma (HNSCC), mCRPC, pancreatic cancer, lung cancer, bladder cancer, mesothelioma, cervical cancer, renal cancer, sarcoma, pheochromocytoma and cancers with PI3K\u002FAKT\u002FmTOR pathway activating mutations using a clinically-validated assay).\n\n Phase 2a:\n\n \\- Histologically proven advanced solid tumour, in line with indications listed below, refractory to conventional treatment, or for which no conventional therapy is considered appropriate by the Investigator or is declined by the potential participant:\n 1. MSS CRC with PIK3CA or HER2 mutation, and\u002For other driver mutation as agreed with the Sponsor (genomic alteration to have been previously identified using a validated next-generation sequencing method performed on either tumour tissue or circulating tumour DNA \\[ctDNA\\]);\n 2. Gastric or gastroesophageal junction (GOJ) adenocarcinoma;\n 3. Clear cell renal cell carcinoma;\n 4. mCRPC\n\n Phase 1 Part B and Phase 2a:\n * Consent to access and analysis of any available archival tissue.\n * Consent for fresh tumour biopsy samples at baseline and on treatment. However, the following exceptions will be permitted if archival tissue is available at the recruiting site:\n\n 1. Patients with mCRPC: biopsies are not required for those whose only safely accessible lesions are bone metastases that lack an accessible soft tissue component.\n 2. For the first 12 participants in each indication: the on-trial biopsy is optional; and the baseline biopsy is mandatory if there is a safely accessible lesion but may be omitted for patients who have no safely accessible lesion, to permit their inclusion in the study. This will continually be assessed through the study.\n * Disease refractory to conventional treatment, or for which no further conventional therapy is considered appropriate by the Investigator or is declined by the participant.\n * Except for mCRPC, at least 1 measurable lesion according to RECIST v1.1, which (in the Investigator's opinion) has had objective radiological progression on or after the last therapy. Potential participants with mCRPC may instead have had PD according to PCWG3 criteria.\n\n 1. Previously irradiated lesions cannot be counted as target lesions unless clearly progressed after the radiotherapy.\n 2. Lesions that are intended to be biopsied should not be counted as target lesions (those undergoing biopsy must have at least one target lesion that is not intended to be biopsied).\n * For indications where anti-PD-1\u002FPD-L1 therapy is standard of care (such as clear cell renal cell carcinoma, or gastric or GOJ adenocarcinoma with elevated PD-L1 expression), patients must have received that therapy and must be considered to have had progressive disease by the Investigator either on, or within 6 months after, that treatment.\n3. Life expectancy of at least 12 weeks.\n4. Eastern Cooperative Oncology Group performance status of 0 or 1.\n5. Haematological and biochemical indices within the protocol specified ranges.\n6. Stable thyroid function tests. Stable doses of thyroxine replacement are permitted.\n7. Aged 18 years or over at the time consent is given.\n\nExclusion Criteria:\n\n1. Radiotherapy (except for palliative reasons), chemotherapy, non chemotherapy systemic anti-cancer therapy (apart from life-long hormone suppression such as luteinising hormone-releasing agents in participants with mCRPC) or investigational medicinal products during the 4 weeks prior to enrolment; or first dose of an immunotherapy during the previous 12 weeks before first dose of HTL0039732.\n2. Ongoing toxic manifestations of previous treatments that are Grade \\>1 per CTCAE v5.0.\n3. Any central nervous system metastases (unless potential participants have had local therapy and are asymptomatic, radiologically stable and have been off steroids for ≥4 weeks prior to enrolment).\n4. Women of child-bearing potential (or who are already pregnant or lactating). Exceptions apply.\n5. Men with partners of childbearing potential. Exceptions apply.\n6. Major thoracic or abdominal surgery from which the potential participant has not yet recovered.\n7. At high medical risk because of non-malignant systemic disease, including active uncontrolled infection.\n8. Known history of current or latent tuberculosis, HIV or Hepatitis B or C infection.\n9. Prior treatment with EP4 inhibitor.\n10. Treatment with selective cyclooxygenase-2 inhibitor in the 8 weeks prior to enrolment.\n11. Known hypersensitivity or intolerance to hydroxypropyl methylcellulose.\n12. Use of systemic immunosuppressive agent in the 2 weeks prior to enrolment. Exceptions apply.\n13. Significant cardiovascular disease.\n14. Known active peptic ulcer disease, or symptoms of gastritis, dyspepsia or gastro-esophageal reflux disease (one or more episodes per week).\n15. Current or planned participation in another interventional clinical trial, whilst taking part in this trial of HTL0039732.\n16. Limited ability to swallow or absorb oral medications.\n17. Any other condition that, in the Investigator's opinion, would mean that the trial is not in the best interests of the potential participant.\n\n Phase 1 Part B and Phase 2a:\n18. Any live vaccines in the 4 weeks prior to enrolment.\n19. Diagnosis of immunodeficiency.\n20. Active autoimmune disease requiring systemic treatment in the 2 years prior to enrolment.\n21. History or clinical suspicion of interstitial lung disease, history of (non-infectious) pneumonitis that required steroids, or current pneumonitis.\n22. Hypersensitivity to atezolizumab or any of its excipients.\n23. Prior adverse reaction to cancer immunotherapy that required steroid or other immunosuppressive treatment or led to discontinuation of that treatment.",{"count":676,"type":21},150,[115,24],"The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other approved anti-cancer therapies, in participants with advanced solid tumours.",[148,680,27,123,681,119,56,63,296,682,297,683,684,685],"Prostatic Neoplasms, Castration-Resistant","Head and Neck Neoplasms","Mesothelioma, Malignant","Kidney Neoplasms","Sarcoma","Pheochromocytomas",[687,688,689,690,691],"EP4 antagonist","Anti-PD-1\u002FPD-L1 agents","PGE2","EP4","COX inhibitor","2025-06-05",{"date":694,"type":32},"2025-06-08",{"date":696,"type":32},"2023-07-13",{"date":698,"type":21},"2027-06",{"name":700,"class":39},"Cancer Research UK",{"id":702,"slug":703,"hasResults":12,"nctId":704,"briefTitle":705,"officialTitle":706,"acronym":4,"eligibilityCriteria":707,"healthyVolunteers":12,"sex":17,"minAge":498,"maxAge":260,"enrollmentInfo":708,"targetDuration":4,"studyType":22,"phases":710,"briefSummary":711,"conditions":712,"keywords":713,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":718,"lastUpdatePostDateStruct":719,"startDateStruct":721,"completionDateStruct":723,"leadSponsor":725,"locationsCount":40},"100507815","feasibility-and-safety-of-robotic-assisted-proximal-gastrectomy-with-double-flap-technique-for-proximal-early-gastric-cancer-100507815","NCT05892289","Feasibility and Safety of Robotic Assisted Proximal Gastrectomy With Double-flap Technique for Proximal Early Gastric Cancer","Feasibility and Safety of Robotic Assisted Proximal Gastrectomy With Double-flap Technique for Proximal Early Gastric Cancer: a Phase II, Multi-center, Single-arm Clinical Study","Inclusion Criteria:\n\n1. 20 years ≤ age ≤ 80 years\n2. The primary gastric lesions were located in the proximal third of the stomach\n3. histologically proven gastric adenocarcinoma (by preoperative gastrofiberscopy)\n4. clinical stage IA (T1N0M0) or IB (T1N1M0 \u002F T2N0M0) according to the 8th edition of the American Joint Committee on Cancer System(Clinical stage was determined based on the finding of endoscopic ultrasonography and\u002For thoraco-abdominal contrast-enhanced computed tomography)\n5. scheduled for robotic assisted proximal gastrectomy with D1+\u002FD2 lymphadenectomy, and possible for R0 surgery by this procedures (Lymphadenectomy is performed on the basis of the criteria of the Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition).).\n6. The preoperative American Society of Anesthesiologists (ASA) physical status was I-III;\n7. The patient's cardiopulmonary function can tolerate robotic assisted surgery;\n8. The subjects have signed the informed consent form.\n\nExclusion Criteria:\n\n1. history of upper abdominal surgery and not suitable for robotic assisted surgery\n2. the tumor invades the esophagus 3cm above gastro-esophageal junction (Z-line)\n3. with other malignant diseases or have suffered from other malignant diseases within 5 years\n4. Excessive tension for esophagogastric anastomosis and require changing the reconstruction procedure\n5. women are pregnant or in lactation period\n6. Suffering from serious mental illness\n7. history of continuous systemic corticosteroid or immunosuppressive drug treatment within 1 month",{"count":709,"type":21},42,[85],"Proximal early gastric cancer can choose radical total gastrectomy or proximal gastrectomy. The patients have poor nutritional status and quality of life after total gastrectomy. Compare to total gastrectomy, the nutritional status can improve after proximal gastrectomy . But if use simple esophagogastric anastomosis for proximal gastrectomy, the incidence of postoperative reflux esophagitis is high, which seriously affects the quality of life, and the short-term outcome is poorer than the total gastrectomy. If the incidence of postoperative reflux esophagitis can be reduced, proximal gastrectomy would be the treatment choice for proximal early gastric cancer, which may more improve both quality of life and nutritional condition than total gastrectomy.\n\nDouble-flap technique is a new surgical reconstruction procedure between esophagus and remnant stomach. It can reduce the occurrence of reflux oesophagitis through reconstruction a simulative cardia. At present, the technique has been carried out in some hospitals in China but still lack large-scale prospective studies and evidence of evidence-based medicine. At present, some retrospective studies have shown that robotic assisted proximal gastrectomy with double-flap technique is safe and effective, and the learning curve is shorter than laparoscopic surgery. The applicant have finished two robotic assisted proximal gastrectomy with double-flap technique cases. Two patients recovered well after surgery, with no occurrence of anastomotic leakage or stenosis and the postoperative quality of life was good. Now we plan to conduct a multi-center, single arm study on proximal early gastric cancer patients(T1N0-1M0 and T2N0M0) to evaluate the feasibility of robotic assisted proximal gastrectomy with double-flap technique , and to evaluate the surgical and oncological safety of this surgical method. Aim to provide initial evidence of evidence-based medicine for its clinical application..",[27],[266,714,715,716,717],"minimally invasive surgical procedures","stomach neoplasm","Gastrectomy","Reflux Esophagitis","2025-05-20",{"date":720,"type":32},"2025-05-25",{"date":722,"type":32},"2024-06-10",{"date":724,"type":21},"2026-12-10",{"name":726,"class":39},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University"]